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ABSTRACT 
Indoleamine 2, 3-dioxygenase (IDO) is an enzyme which is involved in the degradation of L-
tryptophan through kynurennine pathway. IDO induced immunosupression can be clinically 
beneficial for autoimmune diseases. Primary biliary cirrhosis is well defined by autoimmune 
lesion of intrahepatic bile duct epithelial cells. There is evidence that impaired IDO level 
contributes to the development of autoimmunity in PBC. Our aim was to assess the expression of 
IDO in our cell culture model and in PBC patients. Tryptophan metabolites are available and 
could potentially demonstrate utility in PBC. 
 
The current study establishes, for the first time, the expression of IDO in the H69 cell line and 
increase rate of conversion of tryptophan to kynurenine in patients with PBC.  Furthermore, 
clinical biopsies from PBC patients demonstrated that the expression of IDO was observed not 
only in cholangiocytes as described earlier but also in hepatocytes. In the presence of TGF-β 
impaired IDO activity might contribute in the progression of disease scenario. The use of 
tryptophan metabolites could enhance the effects of IDO and compensate for the lack of 
efficiency of existing immunotherapeutic strategies. The positive effect of tryptophan 
metabolites on Human CD4+ T cells to induce polarization toward T-reg phenotype may render a 
prospective means to ameliorate the consequence of immunotherapy for the management of 
PBC. In this study we analyzed that the immunomodulatory enzyme IDO activity providing new 
insight into the pathogenesis of PBC. IDO-mediated immunosupression through tryptophan 
metabolites may be used against the progression of PBC. 
 
Hepatitis C virus (HCV) has infected more than 12 million Pakistani people. Our aim was to 
assess the expression and enzymatic activity of IDO in HCV patients. We observed high 
expression of IDO in HCV induced liver cirrhotic patients. IDO was significantly higher in the 
serum samples of HCV infected patients as compare to the control.  It suggest that IDO may 
involved in the immunosuppression and possibly contribute to progression of HCV infection. 
Our findings advocated that the HCV patients with over expression of IDO might have poor 
prognosis, and IDO may become a newly useful marker for HCV induced liver cirrhosis. Thus, 
blocking IDO might provide new strategies as an adjuvant therapy intervention for HCV. 
 
The modeling of the biological regulatory networks (BRNs) using of Rene Thomas Formalism, 
we observed the critical role of TGF-β and IFN-γ in the suppression and induction of IDO. We 
observe two types of steady states behaviors in the state graph. The cycle shows the homeostasis 
of IDO and TGF-β while IFN-γ is inactive (silent). The stable state shows the high expression 
levels of IFN-γ and IDO while TGF-β is silent.  There is a divergence from the cycle towards the 
stable states and it is observed that this divergence occurs when IFN-γ has expression levels.  In 
cancers condition if we induce TGF-β which is negative regulator of IDO can create the 
homeostasis. Otherwise the expression of IDO can be inhibited by 1-MT. In case of autoimmune 
diseases if we inhibit the TGF-β the induction of IDO may produce homeostasis. Tryptophan 
downstream metabolites can also beneficial in this regard.  
 
Key words: IDO, PBC, HCV, IFN-γ, TGF-β, 1-MT, H69, Tryptophan metabolites, BRNs 
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INTRODUCTION 
 
Indoleamine 2,3-dioxygenae (IDO) is an intracellular heme containing, immunosuppressive 
enzyme that is entailed in the degradation of tryptophan through the kynurenine pathway (Mellor 
et al., 1999). Prior to 1998, IDO was considered to be involved in innate host protection 
 pathogens.  However, in 1998, Munn et al., anticipated that IDO has key function in 
immune regulation, as inhibiting IDO permitted maternal T cells to assault allogeneic fetal tis-
sues during pregnancy in mice. In 2004, several studies had accredited IDO as a constituent of 
the inflammatory reaction associated with infection, allergic diseases, autoimmunity and cancer 
(Mellor et al., 2004; Munn et al., 2004).  
 
IDO has the ability to knob the innate immunity and to regulate antigen specific adaptive 
immune responses in the setting of various chronic infections, tolerance, transplant rejection, 
asthma and immunosupression in the cancers. In case of cancer, different studies documented 
that IDO is expressed in the patients with malignant tumors. IDO enzyme activity is blocked by 
competitive inhibitor 1-MT (Grohmann et al., 2003).  Various studies conducted on mice when 
treating tumor with pharmacological inhibitor of IDO boost tumor-specific immunity. The 
efficacy of chemotherapeutic agents increased when combined with IDO inhibitors during the 
treatment of established tumors (Muller et al., 2006; Munn, 2011) and 1-MT has enrolled in 
Phase II clinical trials of oncology.  
 
IDO has the ability to inhibit pathogen replication in some infectious diseases, in other settings, 
IDO facilitate the perseverance of certain infections such as tuberculosis and Human 
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immunodeficiency virus (HIV) (Favre D et al., 2010; Desvignes et al., 2009) Thus, depending on 
the pathogen IDO may aid or obstruct immune responses against pathogens (Divanovic et al., 
2012). The expression of IDO in autoimmunity and transplantation is well documented and in 
these settings blockade of IDO may evidently aggravate disease severity. 
 
The current finding of novel enzymatic IDO isoform (INDOL-1, IDO-2) also proposes that the 
kynurenine pathway of tryptophan metabolism may be involved in more biological processes 
than formerly considered (Ball et al., 2009). The two IDO enzymes may have a differential 
spectrum of expression and signaling pathway and they vary in their selectivity for inhibitors 
(Lob S et al., 2008). 
 
Over expression of IDO induces immunosuppression and tolerance, it has been established in 
different models that IDO has ability to suppress T-cell proliferation through tryptophan 
depletion (Mellor et al., 2004; Grohmann et al., 2003; Munn et al., 2004). Tryptophan 
metabolites contribute to the immunosuppressive effects of IDO by inhibiting the T-cell 
responses (Terness et al., 2002). At the molecular level, IDO induces immunosupression via two 
well-known pathways, the first one is through depletion of tryptophan, which activates the 
cellular stress response pathway via the kinase GCN2 (general control nonderepressible 2) 
(Munn et al., 2005) and second one is through the generation of tryptophan downstream 
metabolites (Mezrich et al., 2010). IDO can be induced by pro-inflammatory cytokines or by a 
‘reverse signalling’ pathway (Puccetti et al., 2007). 
 
It has been established that human T cells were responsive to the anti proliferative and cytotoxic 
effects of supplemented kynurenines (Terness et al., 2002; Frumento et al., 2003). Kynurenines 
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have pro-apoptotic properties mainly for stimulated cells and Th1 lymphocytes (Fallarino et al., 
2002; Fallarino et al., 2003). The mechanisms by which tryptophan metabolites affect T cells are 
presently ambiguous; there is possibility that they have direct toxic effects or they bind to the 
receptor that provoke T-cell death (Seman  et al., 2003).  The mutual outcome of the tryptophan 
deprivation and augmenting concentration of kynurenines has been revealed to be dependable for 
GCN2 kinase intervened down regulation of the TCR ζ-chain in CD8+ cells abating their 
cytotoxic effector presentation (Fallarino et al., 2006). Furthermore, the depletion of tryptophan 
with augmented generation of tryptophan metabolites endorses alteration of naïve CD4+CD25- T 
cells into a regulatory phenotype (Fallarino et al., 2006). 
 
IDO is induced during inflammation by IFN-γ which is vital in the development of T-cell, in the 
defense against different pathogen and in the induction of immune-mediated inflammatory 
responses. Lipopolysaccharide (LPS), inflammatory cytokines interleukin-1 (IL-1) and tumor 
necrosis factor (TNF) act synergistically with interferon gamma (IFN-γ) to augment IDO 
expression in vitro (Robinson et al., 2003). The rate of tryptophan degradation indicates the IDO 
enzymatic activity and the concentration ratio among Kyn and Trp (Kyn/Trp) can be used as an 
indicator for Tryptophan degradation and consequently an activated immune system 
(Schrocksnadel et al., 2006). 
 
Primary biliary cirrhosis (PBC) is an inflammatory autoimmune disease that marks the 
cholangiocytes of the bile ducts in the liver. Impaired IDO generation confers to the progression 
of autoimmunity in PBC (Oertelt-Prigione  et al., 2008). Deformities in the regulatory cell niche 
are vital to the advancement of autoimmune diseases, but PBC manifests a quantitative decline in 
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the CD4+ CD25+ FoxP3+ lymphocyte (T-reg) compartment which may be a key point in the 
pathogenesis of disease (Lan et al., 2006). It has been speculated that in PBC the destruction of 
the biliary tract is mediated by auto reactive CD4+ and CD8+ T cells (Shimoda et al., 1998; Kita 
et al., 2002). The induction of cellular senescence in both biliary epithelial cells (BECs) and 
hepatic stellate cells has been shown as important in the pathophysiology of various chronic liver 
disease, including PBC (Sasaki et al., 2010). Increased expression of p21 in the damaged bile 
ducts, may participate in the progressive bile duct loss in PBC (Sasaki et al., 2008). p21 protein 
upregulation following the addition of hydrogen peroxide to BECs to mimic the impact of 
oxidative stress (Kirby et al., 2008; Rygiel et al., 2008).  
 
TGF-β is key regulatory cytokine that has role in autoimmunity, and establishing tolerance 
(Rubtsov et al., 2007).  IDO is an essential intermediary that associates TGF-β generation by 
DCs with T-reg differentiation and induction of tolerance (Belladonna et al., 2008). TGF-β 
(Yuan et al., 1998) IL-10 (MacKenzie et al., 1999) and nitric oxide (Thomas et al., 1994) are 
negative regulators of IDO. With the exclusion of IL-10, these regulators are augmented in the 
liver of the PBC patients (Martinez et al., 1995; Neuman et al., 2002). 
 
HCV a member of flaviviridae family (Tan et al., 2002), has infected an estimated 170 million 
people worldwide and patients have high risk of chronic liver diseases and liver cancer (Alter et 
al., 2000; Lauer et al., 2001; El-Serag et al., 2002). The delayed responses of T-lymphocytes are 
linked with chronic HCV infection (Bowen et al., 2005). To understand the pathogenesis of the 
disease and to find out novel therapeutic target is emergent. 
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IFN-γ is a proinflammatory cytokine that is upregulated in the livers of patients with CHC 
(Chronic hepatitis C) (Abbate et al., 2003). The mechanism of IDO induction during HCV 
infection is unknown; upregulation of IDO expression in the liver has been reported in humans 
with chronic infection and HCV clearance was associated with the normalization of IDO level 
(Larrea et al., 2007). Induction of IDO may suppress T-cell reactivity to viral antigen in chronic 
HCV infection. In HCV infected chimpanzees that cleared the infection, the hepatic IDO 
expression was normal but it remained high in those that progressed to chronicity (Larrea et al., 
2007). In humans, T-regs are expended during acute HCV infection (Sugimoto et al., 2003; 
Perrella et al., 2006; Ulsenheimer et al., 2003), maintained during the chronic stage (Sugimoto et 
al., 2003; Cabrera et al., 2004; Boettler et al., 2005; Bolacchi et al., 2006; Ebinuma et al., 2008) 
and lowered to the frequency of control individuals upon spontaneous recovery or treatment 
induced cure from HCV (Sugimoto et al., 2003; Boettler et al., 2005). An increased frequency of 
T-regs at the onset of infection was suggested to predict a chronic infection (Perrella et al., 
2006). Fallarino observed that tryptophan derived catabolites and tryptophan starvation can 
transform naïve CD4+ CD25- T-cells into CD4+ CD25+ and FoxP3+ regulatory T-cells (Fallarino 
et al., 2006). IDO expressing DC enhances the function of T-regs (Sharma et al., 2007). Both 
immature and mature DCs constitutively express IDO protein, which suppresses T-cell 
proliferation in vitro and in vivo (Munn et al., 1999). Tryptophan metabolites produced by IDO 
prevent the T-cell responses (Terness et al., 2002). IDO activity inhibition by1-MT could lead to 
augmented T-cell proliferation in DC-T co-culture in vitro (Munn et al., 2004).  
 
Qualitative formalism of Rene Thomas (Thomas, R. 1978) is widely used for the modeling and 
analysis of biological regulatory networks (BRNs).The logical method proposed by René 
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Thomas was used in modeling of IDO-related BRN which is a useful approach for qualitative 
modeling. TGF-β appears to suppress IFN-γ induced transcription directly and established as a 
likely antagonist of IFN-γ (Devajyothi et al., 1993; Panek et al., 1995). It has been established 
that the regulation of IDO is much more complicated than had been contemplated. In the DC that 
expresses IDO, autocrine production of TGF-βis significant in the establishment of early 
regulatory milieu (Stephen et al., 2009). Acting through Jak1 and Stat1, IFN-γ induces the 
expression of Smad7, an antagonistic SMAD (Hayashi et al., 1997; Nakao et al., 1997) which 
inhibits the interaction of Smad3 with the TGF-β receptor. Both TGF-β and IFN-γ have contrary 
effects on varied cellular functions (Letterio et al., 2003; Czarnieki et al., 1988; Bauvois et al., 
1992; Schmitt et al., 1994; Xiao et al., 1996), but the basis for this antagonism is not known 
(Stark et al., 1998). 
 
However, in cancer patients suffering with immunosuppression, IDO and TGF-β activity could 
be best to stimulate the tumor-specific immune response. Blocking of TGF-β signaling and IDO 
activity can be appropriate approach in this way (Massague, 2008; Popov et al., 2008). However 
kynurenines generated from tryptophan degradation, which contain: L-Kynurenine (Kyn), 3-
hydroxykynurenine (3HK), and 3-hydroxyanthranilic acid (3HAA) can hinder T cell activation 
and propagation (Terness et al., 2002; Frumento et al., 2002). IDO has been suggested to play a 
role in tumor immune escape and inhibition of IDO in vivo could be a promising anti tumor 
adjuvant therapy (Uyttenhove et al., 2003).  
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Specific Aims 
 
We hypothesized that immunoregulatory activity of IDO might have pivotal role in PBC. We 
reasoned that expression of IDO (reported first time in our study) in H69 cell line may offer 
comprehension into the pathogenesis of PBC. The H69 cell line was created by Grubman from 
human intrahepatic biliary epithelial cells (Grubman et al., 1994).  
We thus investigated  
 
(i) The expression of IDO at mRNA level and protein level in H69 cell line 
(ii) The functional enzymatic activity of IDO in the H69 cell line and serum samples of 
PBC patients and controls 
(iii) The expression of IDO in control vs. PBC liver tissues  
(iv) The expression of IDO in control vs. Acute rejected transplanted liver tissues  
(v) To investigate whether kynurenines can modulate the Human CD4+ T cells 
polarization toward T-reg phenotype  
(vi) The expression of IDO in HCV infected Liver biopsies in Pakistani patients 
(vii) The functional enzymatic activity of IDO in the serum samples of HCV patients and 
controls  
(viii) The biological regulatory network (BRN) of IDO through bioinformatics tools in 
disease and homeostasis 
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LITERATURE REVIEW 
2.1 Indoleamine 2,3-dioxygenae (IDO) 
 
 
IDO is haeme-containing enzyme that catalyzes oxidative degradation of tryptophan  
(Grohmann et al., 2003). The enzyme cause oxidative cleavage of double bond at position 2,3 in 
the indole ring, which is also a rate-limiting step in degradation pathway of tryptophan 
(Grohmann et al., 2003; Stone et al., 2002a). IDO is expressed in various tissues and antigen-
presenting cells (APCs) and is involved in many complex immunological factors (Taylor et al., 
1991; Burke et al., 1995; Mellor et al., 2004; Munn et al., 2004). 
 
2.2 Regulation of IDO gene expression 
 
A single gene encodes IDO protein, consisting of 10 exons and is approximately 15-kilo bases 
(kb) in size present at syntenic region of chromosome 8 in mouse as well as human. It has been 
reported that IDO gene is well-conserved (Suzuki et al., 2003). Transcription of this particular 
gene is regulated strictly, influenced by specific mediators of inflammation, and restricted to 
limited cells only. The promoters of IDO genes are more sensitive to some inflammatory 
mediators such as interferon type-I in general and type-II (IFN-γ) in particular (Taylor et al., 
1991; Dai et al., 1990; Hassanain et al., 1993; Mellor et al., 1999). The cells expressing IDO 
after IFN-γ exposure includes DCs, macrophages, endothelial cells and fibroblasts (Taylor et al., 
1991; Burke et al., 1995). IDO induction mediated by IFN-γ occurs collectively through the 
activity of IRF1 and STAT1 (Figure: 2.1) (Chon et al., 1996).  
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Figure: 2.1 IDO enzyme activity. IDO transcription is caused by JAK-STAT signaling by the potent 
inducers of IDO through activation of two important sequences in IDO promoter, which include γ-
activating sequences (GAS) and interferon stimulatory response elements (ISREs). Post-translational 
modifications have not been reported to occur in case of IDO; however it does explain the presence of 
inactive state of enzyme. The assembly of holoenzyme might also serve to regulate the functional activity 
(that is insertion of haeme group), availability of cofactor, inhibitors of active site or redox cellular 
potentials (inhibitors either endogenous, for example nitric oxide, or others such as 1-MT) (Adapted from 
Mellor et al., 2004). 
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Table 2.1: Direct inducer and inhibitors of INDO gene expression 
 
 
 
 
 
 
 
                    
 
Direct 
Inducer  
 
 
IFN-α 
IFN-β 
IFN-γ 
LPS 
CTLA-4 
IL-2 
IL-18 
Inhibitor 
 
 
 
 
 
                   TGF-β 
 
Table 2.2: Indirect inducer and inhibitors of INDO gene expression 
 
 
 
 
 
 
 
                    
 
                  
Indirect 
Inducer  
 
 
TNF-α 
IL-1 
IL-2 
IL-4 
IL-13 
Corticosteroid 
PGE-2 
Estrogen 
Prolectin 
Bacteria 
Viruses 
Inhibitor 
 
 
IL-6 
Atorvastatin 
Acetylsalicylic acid 
Brassinin 
Vitamin C and E 
Sodium sulfate 
Sorbic acid 
Anti-inflammatory plant 
extracts 
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It has been said that inflammation, IDO induction, and IFN-γ are strongly correlated, but IFN-γ 
is not always necessary for induction of IDO. Several other inducers (Table:2.1 and 2.2) include, 
IL-1, lipopolysaccharide (LPS) and tumor necrosis factor (TNF) act in similar manner along with 
IFN-γ to increase expression of IDO in vitro (Babcock et al., 2000; Robinson et al., 2003). 
Nonetheless LPS responsiveness depends crucially on TNF, however does not require IFN-γ 
(Fujigaki et al., 2001) showing the presence of pathways independent of IFN-γ for the IDO 
induction. Certain other cytokines and signaling pathways may adjust IDO expression by 
specific types of cells. Hence, transcription of IDO is a complex process and specific for cell 
type.  
2.3 The functional activity of IDO  
 
IDO enzyme is an intracellular in nature; there is no extracellular or secreted form reported. The 
trophoblast cells are found to express constitutive IDO activity at fetal-maternal interface (Kudo 
et al., 2001; Honig et al., 2004). 
2.4 IDO-2 
Recently, the discovery of a similar gene to IDO changed the whole prevailing paradigm 
(Murray, 2007). Subsequently three groups demonstrated the synthesis of an enzyme having 
capability to degrade tryptophan (Metz et al., 2007; Yuasa et al., 2007; Ball et al., 2009). On the 
basis of similar enzymatic activity and structure to IDO, this enzyme is referred as indoleamine 
2,3-dioxygenase-2, as indoleamine 2,3-dioxygenase-like protein or proto-indoleamine 2,3-
dioxygenase (proto IDO, IDO-2, INDOL1). 
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2.5 Biological function 
The tryptophan-catabolising activity of IDO2 expressed in intact mammalian cells has been 
established (Ball et al., 2007; Metz et al., 2007). 1-methyl-L-tryptophan inhibits the IDO-
1activity and 1-methyl D-tryptophan is selective for the inhibition of IDO-2 (Metz et al., 2007). 
The combination of IDO inhibitors with anticancer drugs, have observed antitumor effects (Hou 
et al., 2007). The expression of IDO2 in DCs and its reticence, suggest that IDO2 enzyme may 
participate in immune escape in cancer (Metz et al., 2007). 
2.6 The fate of tryptophan 
 
The fate of tryptophan, one of the essential amino acids can be one of the following three:  
(i) Protein synthesis 
(ii)  Biosynthesis of serotonin  
(iii)  Kynurenine degradation pathway 
Most of the tryptophan degradation happens through kynurenine pathway (Figure: 2.2) which 
affects biological processes in various ways. One of the consequences of enhanced tryptophan 
degradation is suppression of cell proliferation thus generating anti-microbial or 
immunomodulatory effects (MacKenzie et al., 1999). The same degradation pathway is 
concerned in numerous biological processes ranging from fetus toleration in pregnant females 
through immunomodulation (Munn et al., 1998) to activation of various neurological disorders 
such as cerebral malaria and AIDS- related dementia (Heyes et al., 1989). 
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Fig: 2.2 The alternative pathway of tryptophan metabolism. Tryptophan degraded products 
kynurenine and serotonin (Adapted from Takikawa O, 2005). 
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2.7 Tryptophan and the immune response 
 
Tryptophan is a basic amino acid (AA) that is mandatory for all living organisms for the 
synthesis of proteins and other imperative metabolic functions. However animals lack the 
enzymatic machinery required for synthesis of tryptophan from simpler molecules. The 
tryptophan flux is fueled into the food chain by primary producers. Bacteria, fungi and plants use 
molecules such as phosphoenolpyruvate to synthesize tryptophan. Mammals lack the ability to 
synthesize tryptophan so they need to acquire it as protein which is later hydrolyzed in the 
digestive system into constituent (AA). Dietary tryptophan is transported to the liver; tryptophan 
can then pursue one of the two metabolic pathways. First, it can be disseminated to the blood 
stream where cells of the body can use it for protein synthesis or other functions. Second, 
tryptophan is degraded through kyneurenine pathway (Figure: 2.3). Tryptophan serves as the role 
of a building block for protein synthesis in animals and humans but also acts as a substrate in the 
production of various important molecules (Stone et al., 2001).  
2.8 Immune-related tryptophan breakdown 
 
 
Tryptophan catabolism is mediated by two different enzymes. Tryptophan 2,3-dioxygenase 
(TDO), is mainly found in liver, is highly specific for the tryptophan substrate and is induced by 
tryptophan and metabolic steroids (Salter et al., 1985; Sainio et al., 1990). IDO is express in 
many tissues; IFN-γ is a persuasive inducer of IDO during an immune response (Yoshida et al., 
1981).  
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Fig: 2.3 The tryptophan metabolism by kynurenine pathway (Adapted from Helen et al., 2009). 
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IFN-γ is a secreted by activated T-cells and other leucocytes; IFN-γ has the ability to induce 
ROS (Reactive Oxygen species) and nitrogen species generation in macrophages (Nathan et al., 
1983) and neutrophils (Tennenberg et al., 1993). One of the well documented and inexplicable 
roles of IFN-γ during an immune response is the robust and sustained tryptophan catabolism in 
many different cell types (Werner-Felmayer G et al., 1991; Grant et al., 2000).   
 
The biological significance of IFN-γ mediated tryptophan breakdown has not yet been 
completely understood but it is thought by many researchers that it is a biostatic mechanism 
which acts by cutting off the local tryptophan supply to different pathogens, intracellular 
parasites and cancer cells (Hayaishi et al., 1996; Wood et al., 1991). The antipathogenic and 
antitumor effect of tryptophan depletion has gained reasonable attention in recent years. 
2.9 The Kynurenines 
2.9.1 Kynurenic acid 
 
Kynurenic acid is a neuroprotectant and an endogenous agent generally found in brain at very 
low nanomolar concentrations (Moroni et al., 1988). The inhibitors of kynurenic acid or 
quinolinic acid act on NMDA (N-methyl-D-aspartate ) receptor at very minute concentrations on 
glycine modulatory site (Stone et al., 1993), at glutamate site when greater quantity is present 
and also on the a-amino-3-hydroxy-5-methyl-4-isoxazolepropionate (AMPA) receptors (Stone et 
al., 2002b). Moreover the inhibitor also antagonizes the alpha 7 nicotinic acetylcholine receptors 
(Hilmas et al., 2001) and cause selective activation of G-protein coupled receptor (GPR35) 
(Wang et al., 2004). 
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2.9.2 3-hydroxyanthranilic acid 
 
3-hydroxyanthranilic acid can be obtained either from anthranilic acid oxidation, or hydrolysis of 
3-hydroxykyurenine. 3-hydroxyanthranilic acid is a neurotoxin, on the other hand is involve in 
immunoregulation (Morita et al., 2001; Lopez et al., 2008) In addition, it generates free radical 
(hydrogen peroxide and superoxide) when copper is present (Goldstein et al., 2000). However it 
also has the ability to act as an antioxidant, having property to scavenge radicals efficiently than 
many other antioxidants such as Trolox or ascorbic acid (Christen et al., 1990). Furthermore, it 
may also apply apoptosis on T helper 1 cells (Th1) and murine thymocytes via cytochrome c 
release from mitochondria or caspase-8 activation (Fallarino et al., 2002). This action takes place 
at concentrations quite below than those causing macrophage apoptosis or neurotoxicity and thus 
can explain the immunnoregulatory role of 3-hydroxyanthranilic acid in various disease states 
(Fallarino et al., 2002).   
 
2.9.3 Picolinic acid 
Picolinic acid is zinc and iron chelator and an endogenous neuroprotectant. It is monocarboxylic 
acid (Jhamandas et al., 1990). It is an important growth regulator and possesses antiviral, 
antifungal and antitumor activities. In normal conditions it arrests cell at G1 phase through 
alterations in NAD+ function which can be readily reversed by the addition of nicotinamide 
(Fernandez-pol et al., 1977). 
 
2.9.4 Quinolinic acid 
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Quinolinic acid is an amino acid (Stone et al., 1981). It has been found that when the body is 
participating in a central or systemic immune response, there is an intense increase in the 
quinolinic acid levels and IDO-1 activity. However, the importance of these drastic changes is 
still unclear (Heyes et al., 1992; Flanagan et al., 1995). Infiltrating macrophages, dendritic cells 
and microglia are the key sources of quinolinic acid production in brain under inflammatory 
conditions (Moffett et al., 1993; Brew et al., 1995; Heyes et al., 1996; Heyes et al., 1997). 
2.10 Role of kynurenine pathway metabolites in Immune modulation 
 
During the time period of mid 1990s and present many researchers started looking for the 
importance of different kynurenine metabolites in the immune system. In 2002, almost every 
metabolite of kynurenine pathway was found to have a specific role in the immune modulation 
with effective concentrations in micromolar (µm) range. The initial finding of Mellor and Munn 
in 1998 enlightening that inhibition of IDO is involved in the rejection of allogenic fetuses in 
pregnant mice (Munn et al., 1998). This established that the role of IDO was imperative for the 
continuance of pregnancy (Pfefferkorn et al., 1984).  
 
One of the major aspects of interest for investigators was that whether tryptophan replenishment 
could reverse the effects of IDO activity. This was because tryptophan replacement in a culture 
media reversed the effects of IDO activity and tryptophan depletion theory provided a 
satisfactory explanation to this observation. But as the investigators further explored IDO 
induction in different experimental settings, they came across anomalies that could not be 
completely explained with the concept of tryptophan depletion (Burke et al., 1995; Murray et al., 
1989). Delayed tumor growth was observed in a case where IDO activity was inhibited in mice 
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implanted with lung carcinoma cells (Friberg et al., 2002). Further it was found that kynurenine, 
3-hydroxykynurenine and 3-hydroxyanthranilate were more effective metabolites as compare to 
others. After inhibition with these metabolites, the T cells could not be restimulated. It was 
suggested by the authors that apoptotic cell death was the mechanism through which permanent 
inhibitory effect was mediated. In addition to this, it was found that kynurenine pathway 
metabolites could also be employed to kill B cells and natural killer cells. However, dendritic 
cells were resistant to the apoptosis induced by these metabolites. 
2.11 The Kynurenine Pathway in Disease States 
 
It has been observed that during different pathological conditions, there is an increase in the 
tryptophan degradation along with a noticeable rise in kynurenines in the serum. Furthermore, 
kynurenine pathway mediated tryptophan catabolism is often favorably routed towards the 
generation of quinolinic acid. The pathologies related to the up-regulation of the kynurenine 
pathway include infectious diseases (e.g. HIV, HCV and HPV), neurological disorders (e.g. AD, 
and ALS), malignancy (e.g. hematological neoplasia and colorectal cancer) and autoimmune 
diseases (e.g. rheumatoid arthritis and MS). However, considerable raise in tryptophan levels in 
breast and lung cancer have also been reported (Cascino et al., 1991). 
2.12 The immune system and IDO 
 
Previously, it was considered that IDO is the part of the host defense against pathogens (Taylor 
et al., 1991). It has now become evident that IDO plays important part in the immune system. 
But it is still not obvious whether the effect of IDO is always beneficial for host or not. IDO 
forms a part of innate immune system to fight against various infections. Most of the 
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microorganisms are able to synthesize their own tryptophan while some of them are dependent 
on exogenous tryptophan (auxotrophs). Auxotrophs are easily affected by the depletion of 
tryptophan through IDO (Pfefferkorn et al., 1984; Hayashi et al., 2001). All these finding show 
the association of IDO activity with tryptophan depletion. Although IDO is found to have a 
significant role in inhibition of pathogen replication in vitro, but its biological importance in 
controlling the infections in vivo remains unclear. There lies a possibility that IDO may be more 
helpful to the pathogen as compared to the host. 
2.13 IDO-dependent immune-suppression  
 
The molecular mechanisms by which IDO create immunosuppressive microenvironment are still 
a matter of active exploration. Theoretically the prospects may include the direct effects on T 
cells which are either mediated by the depletion of tryptophan or by downstream tryptophan 
metabolites. These possibilities are not independent of each other; and multiple downstream 
pathways are characteristically triggered by other pathways. Tryptophan depletion was 
recognized as the first mechanism of action for IDO. In addition of high concentration of 
tryptophan to the culture media reverses the antimicrobial effects of IDO. Different studies 
demonstrated that addition of excess tryptophan reverses the IDO mediated T-cell inhibition in a 
similar manner (Munn et al., 1999; Munn et al., 2004; Sakurai et al., 2002; Von et al., 2002). 
However, these metabolites include molecules for instance; 3-hydroxy-anthranilic acid and 
quinolinic acid which have toxic and immunosuppressive effects (Fallarino et al., 2002). The 
cytotoxic effect of externally added kynurenine, picolinic acid and 3-hydroxy-anthranilic acid 
also affects human T-cells (Frumento et al., 2002; Terness et al., 2002). However, it is still 
unclear that how T-cells are affected by the downstream metabolites of kynurenine pathway. 
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These metabolites might be directly toxic or they might bind to a receptor, like other small 
molecules, to trigger the death of T-cells (Seman et al., 2003).  
 
 
 
 
 
Figure: 2.4 Prospective pathways in T cells responding to the effects of IDO (Adapted from Mellor et 
al., 2004). 
However, it is still speculative that how either of them functions in vivo. It is still to be 
investigated that at molecular level which signaling pathways allow T-cells to recognize and 
react to the circumstances generated locally by IDO. It is still not known that how these toxic 
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metabolites are sensed by T-cells. The GCN2 stress-kinase pathway, which is activated by 
amino-acid withdrawal (Harding et al., 2000; Zhang et al., 2003) and the mTOR (mammalian 
target of rapamycin)-signaling pathway (Figure: 2.4), which is inhibited by amino-acid 
withdrawal (Rohde et al., 2001; Gao et al., 2002). 
2.14 IDO in human disease 
 
However, IDO might have an etiological role in various disorders where the protective 
functioning of immune system surprisingly fails to respond and pathological tolerance develops 
to certain antigens which ultimately leads to chronic disease. 
2.15 IDO and cancer 
 
Various human tumors express IDO in vivo (Mellor et al., 2002; Munn et al., 2004; Oyama et 
al., 1998). This might act as a resistance mechanism against activated effector T cells infiltrating 
the tumor. IDO creates immunosuppressive microenvironment (Figure: 2.5). The urine of cancer 
patients has an elevated level of tryptophan catabolites and the reversal of this effect is mediated 
by surgical tumor reductive therapy (Rose et al., 1967). It has been proposed in different studies 
that overexpression of IDO is associated with poor prognosis (Okamoto et al., 2005). 
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Figure: 2.5 Interplay between cells of the immune system and the tumor that promote an 
immunosuppressive environment. Generation of various cytokines (IL10, IL13), chemokines (CCL2, 
CCL22), TGF- β and vascular endothelial growth factor (VEGF) as well as tumors can negatively 
regulate the immune system and eventually promote the expansion and migration of cells. T-effector cells 
which are blocked by T-regulatory (T-reg) cells through both the generation of IL10 & TGF- β can be 
recruited as well as immature dendritic cells, myeloid suppressor cells (MSCs), tumor-associated 
macrophages (TAMs) and  natural killer T cells (NKTs). Host cells as well as the tumor cells have the 
capacity to express IDO, arginase (ARG), inducible nitric oxide synthase (iNOS) and cyclooxygenase 2 
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(COX2). Mature, toleragenic dendritic cells also have the capacity to accumulate lymph nodes in which 
tumor-draining is induced. Interaction with T-reg cells which function to express CTLA4 can be induced 
by IDO activity in DCs which are toleragenic this can promote further T-reg differentiation and 
expansion. (Adapted from Muller et al., 2006) 
 
The level of IDO-positive eosinophil infiltrate was linked with reduced survival (Astigiano et al., 
2005). IDO positive-staining in DCs of the tumor-draining lymph nodes of melanoma patients 
was associated with poor prognosis (Munn et al., 2004; Lee et al., 2003). Moreover, the high 
immunoreactivity of IDO is significantly associated with the frequency of liver metastases. 
Nakamura studied the expression of IDO and the localization of CD4+CD25+Foxp3+ regulatory 
T cells (T-regs) in the development and progression of uterine cervical cancer (Nakamura et al., 
2007). 
2.16 Transforming growth factor 
Proliferation of cancer cells can be directly suppressed at early development of tumor via the 
expression of TGF-β in most tumors which are malignant in nature (Dumont et al., 2003; 
Yingling et al., 2004). Mutations in the TGF-βR, TGF-β, metastatic phenotype, downstream 
signaling proteins such as Smad proteins receptor can be initiated by the evolution of cancer cells 
which occurs by the inhibition of TGF-β-mediated growth. Cancer cells in patients with 
metastatic or advanced tumors can become non responsive to TGF-β as they are overexpressing 
them which can be regarded as a characteristic for profound immunosuppression in these patients 
(Dumont et al., 2003; Yingling et al., 2004). 
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Several studies have examined how T-cell regulates TGF-β function which affects tumor 
immunological response. Early studies focused on the direct effect of TGF-β on CD8+CTLs, as it 
was shown that TGF-β could suppress IL2 production and CTL activation (Herrmann et al., 
1996). CTL function was suppressed in both in vitro and in vivo in tumor cells in which TGF-β 
was transfected (Torre-Amione et al., 1990).  
 
CD4+ TH cells differentiation is also affected by TGF-β (Gorelik et al., 2000; Gorelik et al., 
2002). It has also been observed that TGF-β has also been shown to antagonize TH1 responses 
through suppression of IFN-γ production by natural killer cells (NKs) (Laouar et al., 2005), and 
to block the maturation and activation of DCs by reducing their ability to present antigen and to 
stimulate T-cell proliferation (Strobl et al., 1999).The preliminary role of TGF-β in the context 
of T-reg cells has been controversial, although neutralizing antibodies to TGF-β have been 
shown to reverse immune suppression by T-reg cells in several models of inflammation (Read et 
al., 2000; Seddon et al., 1999). Recent work has revealed a prominent role for TGF-β in the 
peripheral expansion of T-reg cells. 
 
In addition, exposure of CD4+ CD25– cells to TGF-β in vitro induced FOXP3 expression, which 
caused them to differentiate towards a T-reg phenotype that is capable of suppressing CD4+ T-
cell activation (Figure: 2.6) and production of cytokine (Chen et al., 2003). Based on the TGF-β 
directed effects on tumor growth, as well as it potential effects on the immune system, several 
techniques to develop inhibitors of the TGF-β pathway have been investigated.  
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Figure: 2.6 Interaction of enzymes and cytokines associated with immune suppression. 
Cyclooxygenase 2 (COX2), through the production of prostaglandin E2 (PGE2), has a central role in 
regulating the expression of other immunosuppressive modulators, including the enzymes ARG and IDO, 
the cytokine vascular endothelial growth factor (VEGF) and the chemokine CCL22. The type II cytokines 
interleukin IL10, IL13 and IL4, also induce ARG expression, and iNOS regulates both the expression of 
VEGF and IDO as well as the activity of COX2. In addition to its known immunosuppressive effects, 
transforming growth factor-β (TGF-β) might also have positive effects on the immune system by 
inhibiting IDO and iNOS expression. DC, dendritic cell; FLT1, FMS-related tyrosine kinase-1; MSC, 
myeloid suppressor cell; pDC, plasmacytoid dendritic cell; T-reg, regulatory T cell (Adapted from Muller 
et al., 2006). 
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2.17 Primary biliary cirrhosis (PBC)  
 
A chronic cholestatic liver disease such as PBC has mostly affected women in populations 
around the globe (male to female ratio is approximately 1 to 10). PBC primarily affects middle-
aged women. The female predominance may hold an important key to PBC etiology (Prince et 
al., 2002; Kaplan et al., 2005). PBC is a chronic inflammatory autoimmune disease that mostly 
targets the cholangiocytes of the interlobular bile ducts in the liver. Without treatment, it usually 
progresses to cirrhosis and eventually liver failure over a period of 10–20 years. In PBC the 
biliary epithelial cells (BEC) lining small intrahepatic bile ducts are reported to be damaged. 
Biliary epithelial cells loss is typically associated with the significant infiltrate of the 
inflammatory portal tract constituting a mixture of T cells, B cells, natural killer cells 
eosinophils, and macrophages (Terasaki et al., 1993; Yeaman et al., 2000). Recently work is 
been done to identify the immunological parameters of this disease (Jones et al., 1995). Auto-
antibodies in the serum were recognized in case of PBC patients, and were one of the first 
conditions for characterization of the autoreactive response for antigen specificity (Yeaman et 
al., 2000).  
2.18 Pathological Factor in PBC  
 
From immune system point of view PBC is characterized by collapse of immune self-tolerance 
to highly conserved mitochondrial and nuclear antigens. The first autoreactive responses to be 
established in PBC were the serum antibody responses directed at antigens present on the inner 
mitochondrial membrane (antimitochondrial antibodies) (Yeaman et al., 1988; Courvalin et al., 
1990; Yeaman et al., 2000). Both CD4 and CD8 autoreactive T-cell responses directed at self-
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PDC-E2 (pyruvate dehydrogenase complex) have now been widely characterized in PBC 
patients. (Jones et al., 1995; Kita et al., 2002).  
 
 
 
 
 
Figure: 2.7 Sequential models for primary biliary cirrhosis pathogenesis. In this model one (or more) 
factors causes biliary epithelial cell damage, which in turn leads to ductopenia (‘‘upstream’’phase) and 
(‘‘downstream’’ phase). EMT, Epithelial to mesenchymal transition (Adapted from Jones, 2008). 
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Indication of up regulated TGF-β signaling is present in the liver in PBC. IL-6 release is 
enhanced in the PBC liver by the upregulation of the TGF-β signaling (partly by hydrophobic 
bile salts) (Robertson et al., 2007; Mao et al., 2005). In fact, PBC illustrate a quantitative decline 
in the CD4+ CD25+ FoxP3+ lymphocyte (T-reg) compartment (Lan et al., 2006). IDO configures 
the induction and regulation of T lymphocyte proliferation (Munn et al., 1999). In PBC enhanced 
levels of TGF-β were reported (Martinez et al., 1995) and this molecule acts as an IDO 
transcription identified inhibitor (Yuan et al., 1998). Various stimulating factors act in the 
enhanced production of TGF-β (Li MO et al., 2006). 
2.19 Hepatitis C virus (HCV) 
 
A positive strand RNA virus termed as Hepatitis C virus is the solo member of the genus 
hepacivirus in the flavivirus family (M.J. Alter et al., 1992).It is estimated that it affects about 
3% of the world's population and 30% of the patients will eventually develop end-stage liver 
disease after disease progression. Protease inhibitors (boceprevir and telaprevir) are a class 
of antiviral drugs that are widely used to treat hepatitis caused by hepatitis C virus. HCV 
infection and pathological features of hepatic steatosis is variable with the development of 
fibrosis and hepatocellular carcinoma (M.J. Alter et al., 1992). However, multiple approaches to 
evaluate the interaction between the virus and hepatocytes can be used to study the pathology of 
the virus. 
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2.20 HCV and immune responses  
 
The innate immune response is induced in anti-viral or anti-microbial cells in response to 
invading pathogens and can be considered to occur in two phases, initiation and response. 
Pathogens are recognized and genes called interferon stimulated genes by signals from existing 
pattern recognition receptors on the cell surface, in endosomes, or in the cytoplasm (M. Gale et 
al., 2005).  
 
Like many other viruses HCV eradication requires complex coordination of innate and adaptive 
immune responses (Spengler et al., 2007). Lymphocytes responses are associated with the 
elimination of pathogens and eventually the disease (Chang et al., 2003; Racanelli et al., 2003; 
Bowen et al., 2005; Chang et al., 2007; Spengler et al., 2007). 
 
It is difficult to understand the process of adaptive immune commencement in patients who 
develop chronic hepatitis virus, but it seems that the activation of lymphocytes are ineffective 
and decrease in CD4+ and CD8+ is prevalent (Bowen et al., 2005).  
 
Various studies confirmed the involvement of T-reg in HCV infection (Figure: 2.8). In the 
presence of T-reg disease progress and HCV specific immunity become impaired. The function 
of T-regs is enhanced by the DC expressing IDO (Sharma et al., 2007). The mechanism of IDO 
induction during the HCV infection is not clear yet.  
 
It has been reported that there has been an augmented serum kynurenine- tryptophan ratio and an 
up regulation of the expression of IDO in the liver with chronic infection and in many 
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circumstances it has been associated with the clearance of the virus with normalization of the 
patient (Larrea et al., 2007). It has also been observed that in chimpanzees infected with HCV 
there has been a significant IDO expression in cases when they cleared the infection and in cases 
where the disease progressed to a chronic type (Larrea et al., 2007). 
 
 
 
 
 
 
 
Chapter 2  Literature Review 
32 
 
Fig: 2.8 T-regs inhibitory effects during chronic HCV infection. T-regs inhibits the function of 
Effector T-cells through direct and indirect pathway which ultimately impaired the HCV specific 
immunity (Adapted from Angela et al., 2008). 
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MATERIALS AND METHODS 
 
3.1 Culture Media 
3.1.1 Dulbecco’s Modified Eagle Medium (DMEM) 
 
DMEM (Lonza) was supplemented with 100 IU/ml penicillin 100μg/ml streptomycin, 2mM L-
glutamine and 10% heat inactivated fetal calf serum (FCS). This medium was used for 
supporting the growth of H69 cells. 
3.1.2 DMEM-ham’s F12 medium 
 
DMEM-Nutrient F-12 Ham (DMEM-F12) (Lonza) supplemented with 10% heat inactivated fetal 
calf serum (FCS) 100 IU/ml penicillin 100μg/ml streptomycin, 2mM L-glutamine (Sigma 
Aldrich). This medium is used for growth of Bilbray epithelial cell. 
3.2 Propagation of cell lines 
 
Adherent cells in this study were grown in 25 and 75 cm2 flasks horizontally (Griener Bio-one) 
in humidified 37°C incubators with 5% CO2. These cells were harvested every 2-3 days in a 
ratio of 1:3. 
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3.3 Cell line 
3.3.1 H69 Cell line 
 
The human BEC line H69, was originally isolated from dissected portal tracts and immortalized 
via transduction with retroviral SV40 large T antigen by Grubman (Grubman et al., 1994). The 
cells were cultured in T75cm2, T25cm2 flasks (Greiner-BioOne) or chamber slides in media 
containing Dulbecco’s Modified Eagle’s Medium and Nutrient Mixture F12 Ham (2:1) (Sigma) 
supplemented with:  
 1.8x10-4M (24.3mg/l) adenine (Sigma)  
 2x10-9M (1.345ug/l) triiodothyronine (Sigma)  
 5.5x10-6M (1.0mg/l) epinephrine (Sigma)  
 ITS-X supplement (10mg/l insulin, 5.5g/l transferrin, 2.0g/l ethanolamine, 6.7μg/l 
sodium selenite (Invitrogen)  
 1uM (362.46μg/l) hydrocortisone solution (Sigma)  
 10% FCS Biosera  
 PenStrep (100U/ml penicillin and streptomycin) (Sigma) 
3.4 Adherent cells 
 
Cells were grown till 80% confluence when they were passaged by removing the medium and 
washed twice with the sterile phosphate buffer saline (PBS; Sigma-Aldrich) for 2-3 minutes at 
37°C. Trypsin is added to detach the cells. Following this, the detached cells were neutralized by 
equal volume of complete medium and transferred to plastic universal tubes (SLS, North Shields, 
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UK) for centrifugation at 500g for 5 minutes. Pellets were resuspended in complete medium and 
divided into 2-3 flasks. 
3.5 Cell counting and viability 
 
Cells were counted by using modified Neubauer haemocytometer (Reichert). After being 
resuspended, 10μl of cell suspensions were put in the counting chamber beneath the cover slip. 
Cells were counted in at least two of the large squares and the total number was divided by two 
and multiplied by 1x104 to obtain the final number in ml. Cell viability was examined by mixing 
one volume of cell suspension with one volume of 0.2% trypan blue (Sigma-Aldrich) and dye-
excluding cells were counted as viable. 
3.6 Cryopreservation of cells in liquid nitrogen 
 
Cells were detached from 80% confluent flasks spun down at 500g for 5 minutes and 
resuspended in 0.9ml of complete media, following this 0.1ml of dimethylsulphoxide (DMSO, 
Sigma-Aldrich) was added at a final concentration of 10%. The cells were transferred into 
cryovials (Corning) and put in the freezing vessels (Nalgene) which contains Isopropranol. Cells 
were then cooled in -80°C at 1°C/minute overnight and transferred to liquid nitrogen. These cells 
were recovered by thawing at 37°C followed by incubation in 5-10ml of complete medium for 
24 hours where medium was replaced with fresh medium to remove any reaming DMSO.  
3.7 Mycoplasma screening test 
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Cell contamination with Mycoplasma may affect the cell metabolism, viability, proliferation and 
function. MycoAlert kit (Lonza) was used for detection of Mycoplasma enzymes that catalyze 
the conversion of ADP to ATP. This conversion can be measured by bioluminescent reaction due 
to interaction between MycoAlert substrate and ATP. The MycoAlert protocoal depends on 
mixing of 100μl of supernatant media with 100μl MycoAlert reagent and the first reading was 
taken after 5 minutes (A), 10 minutes later the second reading was taken (B). Results were 
calculated by dividing B/A, and result with less than 1 considered as negative whereas results 
more than 1 was consider as Mycoplasma positive. No positive Mycoplasma results were noticed 
in this project. However in case of positive results, cells will be discarded or treated with 
Mycoplasma removal agent (MRA, Serotec) until free of infection. 
3.8 Stressing the H69 Cells with Hydrogen Peroxide  
 
H69 Cells were stressed using 200μM H2O2 (final concentration) when confluent and the media 
changed 2 hours after treatment as previously optimized (Brain et al., 2013). The cells were then 
left post-H2O2 treatment for 0 hour, 6hours, 12hours, 24hours, 48hours, 72hours, 96hours, and 
120hours, before RNA isolation, protein extraction, fixation or harvesting of supernatants. 
3.9 H69 Cells treated with IFN-γ 
 
H69 Cells were treated with IFN-γ 20ng/ml, when confluent and the cells were then left post- 
IFN-γ treatment for 0 hour, 6hours, 12hours, 24hours, 48hours, 72hours, 96hours, and 120hours, 
before RNA isolation, protein extraction, fixation or harvesting of supernatants. 
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3.10 H69 Cells treated with LPS 
 
H69 Cells were treated with LPS 1μg/ml when confluent and the cells were then left post- LPS 
treatment for 0 hour, 6hours, 12hours, 24hours, 48hours, 72hours, 96hours, and 120hours, before 
RNA isolation, protein extraction, fixation or harvesting of supernatants. 
3.11 Tryptophan metabolites 
 
Metabolites derived from tryptophan degradation comprise Kyn, 3HK, 3HAA. These compounds 
with a purity ≥98% were dissolved in RPMI 1640 medium (Gibco BRL) and added to the cell 
cultures in different concentrations ranging from 0 to 100μM.  
 
 
Tryptophan metabolites Catalogue number 
L-kynurenine (Kyn) (Sigma Aldrich)   K8625 Sigma 
3-hydroxykynurenine (3HK) (Sigma Aldrich)          H1771 Sigma 
3-hydroxyanthranilic acid (3HAA) (Sigma Aldrich)   148776 Aldrich 
 
Table 3.1 Tryptophan metabolites and their Catalogue number 
3.12 General Molecular Biology  
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3.13 RNA isolation 
 
In order to avoid RNA degradation caused by RNase contamination, RNA isolation was carried 
out under strict rules of high decontamination. These included decontaminating bench, racks, 
micropipettes, gloves and other equipment with RNase-ZAP (Sigma-Aldrich) followed with 
alcohol. Cells were grown till 70-80% confluency, then medium was removed, cells were 
washed with PBS and 1ml RNAzol B reagent (Sigma-Aldrich) was added to 1x107 cells and left 
for 5 minutes. RNAzol B allows cell lysis and solubilisation by forming complexes of RNA, 
water and thiocyanate. Cells were removed by scrapers into 1.7ml eppendrof tubes and left at 
room temperature for 5 minutes. 200 μl (1:5 RNAzol) of pre-chilled chloroform (denatures the 
protein) was added and tubes were shaken vigorously for 15 seconds, left on ice 2-3 minutes and 
centrifuged for 15 minutes at 12000 g in 4°C centrifuge. The upper aqueous layer was gently 
removed to 1.7 ml eppendrof tube and mixed well with equal volume of propan2-ol 
(Isopropranol, BDH LTD, UK) and left on ice for 10 minutes. Tubes were then centrifuged at the 
12000 g for 10 minutes. Following that the supernatants was removed and pellets were washed 
with 1 ml of 75% ethanol by centrifugation for 5 minutes at 7500g. Supernatant was removed 
and pellets were left to air dry. The RNA was finally reconstituted in 50 μl Diethyl 
pyrocarbonate (DEPC) treated water. 
3.14 Nucleotide quantification 
 
RNA was quantified by spectrophotometer (Biophotometer, Nanodrop). One drop (1μl) of 
nucleotide was measured at O.D of 260/280 and 260/230. The 260/280 value gives a good clue 
of the purity of RNA whereas 260/230 ratio gives an idea about the nucleotide contents. Values 
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of 260/280 more than 2 were considered for good quality and samples were used for further 
steps. In case of 260/280 value less than 1.8 RNA sample was discarded and the whole procedure 
was repeated. 260/280 values lower than 1.8 indicate the presence of protein phenol or other 
contaminants. 
3.15 RNA separation by gel electrophoresis 
 
To examine its integrity, each RNA sample was run on a 0.8% Agarose gel with Ethedium 
bromide (final concentration 0.5μg/ml). This gel was electrophoresed in tri-acetate EDTA (TAE) 
buffer (0.007 M Tris-acetate and 0.001M EDTA, pH 8.0) and visualized by UV light. Intact 
subunits (no smears) of 28s and 18s with a ratio of 2:1 respectively were considered as a good 
clue of RNA integrity. 
3.16 cDNA synthesis 
 
Complementary DNA (cDNA) is synthesized from RNA by reverse transcription to produce a 
single strand of DNA. cDNA was obtained from RNA using superscripts III reverse transcriptase 
(Invitrogen), starting from 5 μg RNA for each tube with 1μl oligo dT12-18 primer or random 
hexameres and 1μl of dNTP (10mM) in total volume of 11 μl. Tubes were incubated at 65°C for 
5 minutes. The mixed was chilled at 4°C for one minute and centrifuged briefly, then 4 μl of 5x 
first strand buffer, 1 μl of DTT and 1μl of superscript III enzyme were added to each tube and 
mixed by gentle pipetting. Tubes were incubated at 50°C for 50 minutes followed by 15 minutes 
at 70°C before cooling. Incubation was performed in PCR thermal cycler (Hybaid). 
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3.17 Gel electrophoresis 
 
Agarose gel electrophoresis was carried out to visualize DNA product such as after conventional 
PCR and DNA fragments. The technique depends on the separation of DNA products upon their 
sizes compared to DNA ladder 100bp (Promega) or 1kbp ladder (Fermentas). The agarose was 
dissolved in 1x TAE buffer and an electric field was applied that allowed DNA fragments to 
migrate towards the positive electrodes according to their negative charges. A definite weight of 
agarose (w/v), depending on the final concentration required, was dissolved in 50ml of TAE 
buffer and boiled in microwave, cooled and 0.5μg/ml of Ethedium Bromide was added. Gels 
were prepared with different concentration between (0.7-1.5 %) depending on the expected sizes 
of DNA fragments. 
3.18 Quantitative PCR 
 
Real time PCR is a method developed for quantifying DNA that allows detection of amplified 
DNA at higher sensitivity of detection than conventional PCR. Here the amount of quantified 
DNA is linked to fluorescence intensity by binding to fluorescent reporter molecule. In 
conventional PCR the amplified DNA is detected at the end of the reaction. Quantitative PCR 
(qPCR) measures the fluorescence at each cycle as the amplification is still in progress 
(exponential phase) before the consumption of the reagents and the accumulation of inhibitors. 
Fluorescence reporter molecules such as double-stranded DNA binding dye or dye labeled 
probes are used for monitoring the progress of amplification reaction. The cycle number where 
the amplification crosses a definite threshold fluorescence level is known as threshold cycle 
(CT). The probes used in this study were hydrolysis probes (Taq Man) which are sequence 
Chapter 3  Materials and Methods 
41 
 
specific comprised basically of oligonucletide labeled with FAM dye and TAMRA quencher. 
Taq Man primers generally contain additional sequence to the primer known as the probe. This 
probe anneals to the same strand of the targeted sequence closely downstream the primer site. 
The fluorescence reporter dye (FAM) is attached to the 5’ end whereas the quencher is attached 
to the 3’ end of the probe. Fluorescence from the reporter is quenched as long as the reporter and 
the quencher stay close together. When polymerization extends Taq DNA polymerase encounters 
the 5’end of the probe. Taq polymerase then degrades the 5’end of the probe. Taq polymerase 
degrades the 5’end of the probe releasing the reporter dye and the quencher which results in 
fluorescence activity. 
 
 
 
Fig: 3.1 Diagram representing three stages of qPCR: cycling and comparison of method of product 
detection between qPCR and traditional PCR. Adapted from SABiosciences. 
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Fig: 3.2 Diagram showing primer probes fluorescence during real time PCR: Real time PCR 
experiments were performed in 96 well plates using master mix (Stratagene) with high Rox while primer 
probes were ordered from TaqMan Gene expression Assay with FAM dye that helps in fluorescence 
normalization relating to pipetting errors and instrument limitations. One tenth of c (2μl) was used as 
template in each reaction (20 μl). qPCR experiments were run in Applied Biosystem Prism 7000 machine 
with the following conditions: 
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Temperature (°C) Duration (Minutes) Cycle number 
50 2 1 
95 10 1 
95 15 seconds 40 
60 1 40 
4 hold  
 
Table 3.2 qPCR experiment conditions 
Each well had a 20μl reaction volume as follows: 10μl of 2x master mix (high ROX), 1 μl of 
primer probe (20 x), 2μl of cDNA were added and the volume was completed to 20μl with Rnase 
free water (8 μl). 
 
Components Volume (μl) 
2x master mix 10 μl 
cDNA 2 μl 
Prime Probe 1 μl 
H2O 7 μl 
Complete volume 20 μl 
 
Table 3.3 Contents of qPCR tube reaction 
Comparative CT method (ΔΔCT) 
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For DNA quantification and data analysis the comparative quantification method was used. This 
method was chosen to compare large number of targets with a house keeping gene without the 
need to run a standard curve for each assay. In this method the house keeping gene served as a 
reference for comparison with a target gene. qPCR experiments were run in triplicates in 96 well 
plates and CT values were obtained. ΔΔCT values were calculated for resting (non-stimulated) 
and stimulated cells for each of the targeted gene in each experiment. Fold change was expressed 
as the value of 2- ΔΔCT and ΔΔCT values were calculated as follows: 
ΔΔCT= ΔCT (calibrator) - ΔCT (unknown). 
Where CTTa is the CT value for targeted gene and CTRa is CT value for reference gene.  
ΔCT calibrator= (CTRa-CTTa) and 
ΔCT unknown= (CTRa-CTTa). 
ΔCT data analysis was carried out using REST-2009 software. 
3.19 Probes 
 
Human exon junction spanning probes do not detect any amplified genomic DNA. These primers 
probes were ordered from (Applied Biosystem), TaqMan Gene Expression Assay. 
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Primers-probe Catalogue number 
GAPDH Hs02758991_g1 
IDO-1 
Hs00984148_m1 
IDO-2 
Hs01589373_m1 
TGF-β1 Hs00998133_m1 
TGF-β2 Hs00234244_m1 
p21 Hs00355782_m1 
 
Table: 3.4 Primer probes for RT-PCR (Applied Biosystem, TaqMan Gene Expression Assay). 
3.20 Standard curve and Efficiency Test (Validation) 
 
A standard curves for each of the reference and targeted genes were made using the same 
concentration of cDNA. Using two fold serial dilutions, the CT numbers and the logarithmic 
values of dilutions were calculated to express the slope equation and PCR amplification efficacy. 
The slope of standard curve was used to estimate the PCR amplification efficiency of real time 
PCR reaction. The efficiency was calculated from the equation: 
Exponentional amplification=10(-1/slope)  
Efficiency= [10(-1/slope)]-1, i.e. if the slope is -3.3 the amplification will be 2.0092 and efficiency is 
1.0092 which means 100% efficiency. The efficiency of an optimal PCR should be between 90 
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and 110%. Efficiency of qPCR was investigated and the procedure was used only after achieving 
validity of amplifying of around 100%.  
3.21 Protein chemistry  
3.22 Protein extraction  
 
Protein was extracted from cells using a lysis buffer (50mM Tris, 150mM Nacl, 0.5-1% NPO4, 
phosphate inhibitor) which was supplemented with one tablet of protease inhibitor (Complete 
Mini Protease Inhibitor cocktail, Roche) for each 10ml. Cell were grown in 25 cm2 flasks till 70-
80% confluency and medium was removed, cells were washed in PBS and detached by EDTA-
Trypsin. Then cells were centrifuged and pellets were treated with 200μl lysis buffer, mixed well 
and left on ice for 15minutes. These lysates were sonicated till frothing and centrifuged at 20,000 
g for 20 minutes. The supernatant was removed to clean Eppendrof tubes where they were used 
for protein assay.     
3.23 Protein assay 
 
Protein concentration was estimated by using Bicinochoninic Acid (BCA) kit (Pierce). The assay 
basically depends on detecting protein by the Biuret reaction. In this reaction, peptides bind to 
cupric ions and form a colored chelate complex under alkaline condition where Cu+2 is reduced 
to Cu+. Then one Cu+ ion reacts with two molecules of BCA forming a purple-colored product 
that exhibits absorbance at 562nm wavelength. Protein concentration was estimated in reference 
to protein standard curve made using serial dilutions of a known concentration of BSA protein. 
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3.24 SDS-PAGE 
 
SDS-PAGE, sodium dodecyl sulphate polyacrylamide gel electrophoresis, is a procedure that 
separates different proteins depending on molecular weight rather than negative charge. SDS 
allows all proteins to have high negative charge so they travel according to their molecular sizes 
when an electrical field on acrylamide is applied. SDS-PAGE consists of resolving component 
and stacking component which were prepared as shown in table.  The gel was set up in running 
tank with vertical electrophoresis apparatus (Bio-Rad).      
   
Material Resolving gel 10% Stacking gel 5% 
H2O 4ml 3.4ml 
30% acryl amide mix 3.3ml 0.83ml 
1.5 M Tris, pH: 8.8 2.5ml - 
1M Tris, pH: 6.8 - 0.63ml 
10%SDS 0.1ml 0.05ml 
10% Ammonium 
persulphate (APS) 
0.1ml 0.05ml 
TEMED 0.004ml 0.005ml 
 
Table: 3.5 components of 10% resolving and stacking acrylamide gels.  
10% acrylamide gel was used to fractional proteins of molecular sizes between 15 and 170 kD. 
After sample loading, the gel was immersed in running buffer (25mM Tris, 250mM glycine and 
Chapter 3  Materials and Methods 
48 
 
0.1% SDS with pH: 8.3) and electrical current of 80-120 V was applied. A protein marker 
(Fermantas) was run with the proteins as a size reference. Equal concentrations of protein 
samples (10-30μg) were loaded after being mixed with 1x SDS loading buffer (50mM Tris, 
100mM dithiotheritol DDT, 2% SDS, 10% glycerol and 0.1% Bromophenol blue) and boiled at 
100°C for 5 minutes. 
3.25 Western blotting 
 
After running the proteins on acrylamide gel, protein bands were transferred to polyvinylidene 
difluoride (PVDF) (Amersham) membrane by a procedure known as gel transfer. First the PVDF 
membrane was immersed in methanol for 30 seconds, then in distilled water for 1-2 minutes. 
Electrophoresed gel was taken from the plates and immersed in transfer buffer which consists of 
3.03g/1 Tris-base, 14.4g glycine, 200ml methanol and the mix was made up to 1000ml in 
distilled water. The electro-blotting cassette was preassembled in the transfer buffer and PVDF 
membrane was put over the gel that allows transfer of proteins from the gel to the PVDF 
membrane. The cassette was then put in transfer tank, immersed with transfer buffer and an 
electrical field was applied with 30V overnight with the cassette cooled by running water. 
The membrane was removed from the cassette and blocked in 5% non-fatty milk (Marvel) or 5% 
BSA in TBS-T (5mM Tris, 150mM Nacl, 0.1% Tween-20 with PH: 7.4) for one hour. Primary 
antibody was added in blocking buffer for at least one hour at room temperature or at 4°C 
overnight. Then membrane was washed three times with TBS-T and secondary antibody 
horseradish peroxide (HRP) conjugated (Sigma-Aldrich) in blocking reagent for one hour at 
room temperature. Afterwards membrane was washed three times with TBS-T. Washing and 
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incubating steps were performed on shaking incubator. Bound antibody was visualized by 
incubating the membrane with enhanced luminol-based chemiluminescence (ECL) substrate 
(Pierce, Thermo Scientific). The working reagent was prepared by mixing one volume of reagent 
A with one volume of reagent B. Appropriate volume (5ml) of the working reagent was put on 
the membrane for 5 minutes. This substrate allows the oxidation of luminol by HRP which 
results in emission of light. The membrane was then sealed in an appropriate cassette for 
exposure to X-ray film (Kodak). 
 
Primary antibody Catalogue number 
Anti-Indoleamine 2, 3-dioxygenase antibody (abcam) ab55305 
GAPDH antibody (FL-335) (Santa Cruz) Sc 25778 
 
Secondary antibody Catalogue number 
Anti-Mouse IgG Peroxidase antibody (Sigma) A9044 
Anti-rabbit IgG HRP-Linked antibody (Cell signaling)  7074 
 
Table 3.6 Primary and secondary Antibodies and their catalogue number 
3.26 Flow Cytometry 
3.26.1 General Principle 
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Flow Cytometry (FACScan, Becton Dickinson) measures cells quantitatively and qualitatively as 
the machine recognizes cell numbers and cell types. The cells are forced in to a narrow stream so 
they are counted one at a time. At this point the cells are intercepted by a laser beam of known 
wavelength (generally 488nm) that stimulates the cells to emit light. This light may be scattered 
at two levels known as forward scatter (FSC) and side scatter (SSC). FSC light is scattered at low 
angle with laser beam that generates a signal which is proportional to the cell size. SSC light is 
scattered at 90° angle with the laser beam which is proportional to the granularity of the 
cytoplasm. Data from deflected light are controlled by a computer unit for each cell and this 
information allows determination of each cell’s number and type. In case of fluorochrome 
labeling, for example with a FITC conjugated antibody, light of different wavelength will be 
emitted after exposure to the laser beam. The emitted light is measured by photomultiplier tubes 
equipped with filters to measure only light at a correct wavelength. The photomultiplier converts 
fluorescence into electrical signals which are proportional to the number of excited molecules.  
3.27 Isolation of CD4+ T cells  
 
Take 10 ml whole blood in the heparin tube. Added Rosette Sep Human CD4+ T cell enrichment 
cocktail at 50μl/ml of whole blood (500 μl/10ml), incubated 20 minutes at room temperature. 
Diluted sample with an equal volume of PBS +2% FBS and mix gently. Then layered the diluted 
sample on top of the density medium. Centrifuged for 20 minutes at 1200 X g at room 
temperature, with the break off. Removed the enriched cells from the density medium: plasma 
interface. Washed enriched cells with PBS+ 2% FBS. Isolated CD4+ T cells (1x105 cells/well) 
were stimulated with anti-human CD3 and CD28 beads (Dynabeads Human T-activator 
CD3/CD28 bead/cell, Invitrogen, Catalogue no:111.31D) in the presence of tryptophan 
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metabolites 3HK, 3HAA Kyn, (Sigma) 50μΜ in each well and TGF-β1 (R&D Catalogue 
no:100-B) 10ng/ml as control in 6-well plates for 5 days. 
3.28 Intracellular staining of T-regulatory cell 
 
Intracellular staining for FOXP3 was carried out using a FOXP3 intracellular staining kit 
(eBioscience). This kit has been formulated and optimized to stain a number of FOXP3 
monoclonal antibodies including the PCH101 clone. Intracellular staining was conducted 
according to the manufactures specifications. Briefly, Cells suspended in FACS tubes were 
pelleted by centrifugation at 500G for 5 minutes. Following removal of the supernatant, cells 
were fixed in a fix/perm buffer (1 part fix/perm concentrate to 3 parts fix/perm diluent) for 30 
minutes at 4°C. Cells were then washed and centrifuged in (x10) permeabilisation buffer at 500G 
for 5 minutes followed by 1 hour incubation with the primary antibody at 4°C. Finally, cells 
were washed twice in permeabilisation buffer before being re-suspended in FACS buffer (PBS 
+2%FBS) and analyzed using FACS Canto II.    
Components Catalogue number 
Anti-Human Foxp3 APC (eBioscience) 17-4776 
Fixation/Permablization concentrate (eBioscience) 00-5123 
Fixation/Permablization Diluent (eBioscience) 00-5223 
Permablization Buffer (10X) (eBioscience) 00-8333 
 
Table: 3.7 Contents of Intracellular staining of T-regulatory cell 
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3.29 High-Performance Liquid Chromatography (HPLC) 
 
Serum samples taken from PBC patients were examined using HPLC. A standard solution 
containing L-Tryptophan and L-Kynurenine (Sigma-Aldrich) were primed from 1 mg ml−1 stock 
solutions in 0.1 % formic acid (Fluka Analytical). Four serial dilutions (fourfold) of the mixed 
standards (100 μg L-Tryptophan ml−1, L-Kynurenine 10 μg ml−1) were primed to create a four 
point calibration curve. Serum samples (50 μl) and standards were mixed with 5 μl 2.4 M 
perchloric acid (Fisher Scientific) including 75 μg ml−1 of the internal standard, L-Tryptophan. 
All samples and standards were adjusted to a final concentration of 1 % trichloroacetic acid 
(Sigma-Aldrich) and centrifuged and the supernatant was analyzed. 
3.30 Colorimetric assay 
 
Kynurenine was measured spectrophotometrically (Takikawa et al., 1988; Grant et al., 2000). 
50μl of 30% trichloroacetic acid was supplemented to 100μl of the H69 cells culture supernatant, 
vortexed and centrifuged at 10,000 rpm for 5min. 75μl volume of the supernatant was then added 
to an equal volume of Ehrlich’s reagent (100 mg of pdimethylbenzaldehyde, 5ml of glacial acetic 
acid) in a microtiter plate well (96-well format). Optical density was measured at 492-nm using a 
Dynex Technologies microplate reader. A standard curve of defined kynurenine concentration 
(0-100μM) permitted analysis of unknowns. 
3.31 Immunofluorescence and Densitometry  
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For immunofluorescence H69 cells were seeded onto 8 well glass chamber slides at 90,000 cells 
per chamber in 250μl medium and grown until confluent. Cells were treated with IFN-γ, LPS and 
H2O2 as described above and left for 0 hour, 48hours and 72hours. Cells were washed with PBS 
prior to fixing with 4% phosphate-buffered paraformaldehyde for 30min at room temperature 
(RT). Cells were permeabilised using 0.1% Triton X-100 in PBS for 15min RT and then blocked 
using 5% BSA in PBS for 60min RT to minimize non-specific antibody binding.  
The concentration of the primary antibodies in 5%BSA/PBS used in the immunofluorescence 
experiments had been previously optimized in our group (Table: 3.8) and all were incubated for 
48hours in a humidified chamber at 4°C. Slides were then washed 3 times with PBS prior to 
incubation with secondary antibody [FITC-conjugated anti-mouse or anti-rabbit (DAKO 
1:100/1:160)] and incubated for 24hours at 4°C and then again washed 3 times with PBS. The 
slides were stained with DAPI (1:3000; 30min RT). Slides were mounted with Fluoromount 
medium (Sigma) and stored at 4°C until analysis. 
Antibody Manufacturer Concentration 
 
IDO 
 
abcam 
 
1:100 
 
Table: 3.8 Antibodies used for Immunofluorescence and their concentration 
3.32 Laser Scanning Confocal Microscopy (LSCM)  
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To visualize immunofluorescence emission spectra a Leica SP2 UV laser-scanning confocal 
microscope was used. Areas of interest were selected and imaged to measure the FITC (green, 
excitation 488nm, emission 510-535nm) and DAPI (blue, excitation 345nm, emission 456-
460nm) staining at 40 x magnifications. A representative “Z-stack” of images was then examined 
for fluorophores localization and morphological analysis.  
LSCM has many advantages when compared against conventional microscopy. Laser light has 
the benefits of being both accurate, monochromatic and coherent minimizing problems 
associated with chromatic and spherical aberration found in conventional microscopy. Multiple 
planar images are amalgamated in a “Z-stack” allowing visualization of the whole cell which 
represents the final image used in densitometric analysis.  
3.33 Densitometry  
 
Densitometry is the quantitative measurement of optical density in light-sensitive materials. 
ImageJ software was used to perform densitometric analysis of the resulting confocal images as 
per software guidelines. 
3.34 Laboratory procedure 
 
All experiments were carried out under the safety policy of Newcastle University and the 
Institute of Cellular Medicine (ICM), and National University of Science & Technology,  in 
accordance of university rules of “safe working and biological hazard”, safe working with the 
chemicals in laboratory’ and ‘A basic Guide for Radiation workers’. Experiments involving the 
use of potent carcinogens and toxins, a COSHH ‘control of substances hazardous to health’ a risk 
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assessment was followed. Cell culture work was performed in compliance with regulation of 
BIO-COSHH class II risk assessment with guidelines produced in ICM.  
3.35 Patients  
 
Studies were conducted under local regional ethics committee approval (reference: REC 
06/Q0905/150). Samples included serum collected for the purposes of research and excess 
biopsy tissue from diagnostic procedures. All samples were anonymised. In order to discount the 
variable effects due to gender difference, all patients with PBC and the healthy controls included 
in the study were females. The enzymatic activity of IDO investigated in the serum samples from 
71 subjects (47 PBC cases, 24 controls). Liver sections from patients with PBC (n = 5), HCV 
(n=35), healthy controls (n=5), were used for immuno-histochemical studies. Samples 
represented excess liver tissue that had been taken for diagnostic purposes; each sample was 
identified by means of a number allocated by the Cellular Pathology department. For this study 
blood samples were collected from HCV infected patients. Patients of who were HCV positive (n 
= 100). Individuals of who were healthy control (n = 100), and negative for HCV, were enrolled 
in this study. 
3.36 Sample collection and storage  
 
Blood sample of the patients were collected in BD vacutainer collection tubes (Becton 
Dickenson, USA) and were shifted to 4 °C. Serum was isolated from the blood after 
centrifugation at 12000 rpm for 2 minutes, divided into 140 μl aliquots and was stored at -80C° 
for further use.  
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3.37 Immunohistochemistry 
 
After de-paraffinization, sections were subjected to antigen retrieval by 1minute in pressure 
cooker in Tris/EDTA buffer Ph 8.0- rapid cool in running tap water. Then washed with Tween 
20 (PBS-T) TBS. Sections were then soaked in 3% H2O2 methanol solution for 5 min, followed 
by 15 minutes each in biotin blocking solution and washed with TBS 3X for 5 minutes.  To 
prevent non-specific staining incubated at room temperature for 1 hour in 20% normal swine 
serum in TBS. Anti-Indoleamine 2,3 dioxygenase antibody (abcam)/  Anti-FOXP3 antibody 
(abcam 22510) was applied for 1 h at the concentration of (1:100) in normal swine serum at 4°C 
in a humidified chamber for overnight. After three washes with TBS for 5 minutes, and 
biotinylated goat anti mouse IgG (Vector) 1:200 in normal swine serum was applied as 
secondary antibody for 1 hour at room temperature in a humidified chamber. After three washes 
with PBS, slides were developed with diaminobenzidine (DAB) (Peroxidase substrate Kit), and 
counterstained with Mayer’s hematoxylin (DakoCytomation) and staining visualized with an 
optical microscope (Provis AX-70, Olympus, Melville, NY). 
3.38 Statistical Analysis 
 
Statistical analysis was carried out using GraphPad Prism 3.0 software. Unless otherwise noted 
graphed data represents the mean value of an experiment conducted in triplicate and error bars 
represent standard error of the mean. Commonly a one-way analysis of variance (ANOVA) was 
performed with Tukey: Multiple comparison test and unpaired t test, if significance reached 
p<0.05. 
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3.39 Graph of Interactions 
 
Qualitative formalism of Rene Thomas (Thomas, R. 1978) is widely used for the modeling and 
analysis of biological regulatory networks (BRNs). The BRN is first modeled as directed graph 
where nodes represent biological entities (for example genes or their products mRNAs and 
proteins) and edges represent their interactions (activations and suppressions). Edges are further 
labeled with type of interactions (+ for activation and – for inhibition) and positive integers 
representing threshold of interactions. BRN contains feedback loops: a negative feedback loop 
has odd number of inhibitions while a positive feedback has either all activations or even number 
of inhibitions. These feedback loops have important role in the dynamics of BRNs (Thomas, R. 
1978; Thomas, R. 1990).  
 
3.39.1 Qualitative Modeling 
 
The qualitative modeling formalism of R. Thomas (also known as kinetic logic) is a multivalued 
logic. Genes’ expressions pass through different qualitative (discrete) levels. These levels can be 
determined from the highest threshold of a biological entity in the BRN. For example if the 
threshold is 1 then there are two possible levels: low level or 0 level and high level or 1 level. 
Similarly if the highest threshold is 2 then there are three possible qualitative levels: 0, 1 and 2. 
If all the highest thresholds of entities are 1 in the BRN then kinetic logic can be called Boolean 
logic and hence Boolean functions are associated to each entity to find the expression levels of 
that entity. All entities will be thus considered as Boolean variables (with two possible levels: 0 
and 1). Once the Boolean functions are defined then the dynamics of the BRN can be determined 
in order to observe its steady state behaviors. In the IDO-related BRN all entities have 1 as their 
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highest threshold. Hence we define the following Boolean functions for theirs dynamics. 
 
 
𝑓(𝐼𝐹𝑁 − 𝛾) = 𝑇𝐺𝐹 − 𝛽̅̅ ̅̅ ̅̅ ̅̅ ̅̅ ̅ (1) 
𝑓(𝐼𝐷𝑂) = 𝑇𝐺𝐹 − 𝛽̅̅ ̅̅ ̅̅ ̅̅ ̅̅ ̅  +  𝐼𝐹𝑁 − 𝛾 (2) 
𝑓(𝑇𝐺𝐹 − 𝛽) =  𝐼𝐹𝑁 − 𝛾̅̅ ̅̅ ̅̅ ̅̅ ̅̅ ̅. 𝐼𝐷𝑂 (3) 
 
In the above equations the function represents the evolution tendency of an entity. The symbols, 
bar, “+” and “.” represent the Boolean operators logical NOT, logical OR and logical AND 
respectively.   Functions (1) depicts that when TGF-β is absent then expression level of IFN-γ 
will evolve towards high level (level 1) else (when TGF-β is high) its expression will degrade 
towards low level (level 0). Function (2) represents the evolution of IDO: when IFN-γ is present 
or TGF-β is absent then IDO will evolve to level 1 else it evolve to level 0. Function (3) show 
the expression tendency of TGF-β: it evolve to level 1 only when IDO is at level 1 and IFN-γ is 
absent.  In the qualitative modeling of R. Thomas entities evolve asynchronously hence the 
functions which evolve a system from a configuration of expression levels of the entities will 
produce  a new configuration with a single change of expression level in the next configuration. 
For example,  if the current configuration is (0,0,0) for the three entities of  IFN-γ, IDO and 
TGF-β then their next configuration according will be (1,0,0)  and  (0,1,0)  instead of the 
synchronous evolution  (1,1,0). We observe the steady states behaviors:  cycle and stable state by 
using these functions which validate our assumptions of the Boolean operations in these 
functions. 
3.39.2 Tool for Qualitative Modeling and Analysis: 
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GenoTech (Ahmad J, 2009) is a tool that facilitates the qualitative modeling and analysis of 
BRNs.  This tool has graphical user interface (GUI) where BRN can be defined as a directed 
graph. The evolution of entities are governed by logical parameters represented symbolically as 
Ke,{resources} and where e is the biological entity and resources are the activators of e when 
they are above their thresholds or they can be the inhibitors of e when they are below their 
thresholds (Thomas, R, 1990).  The current version of GenoTech does not support the evolution 
of entities through   Boolean equations (for example 1-3).  It is easy to convert Boolean functions 
into logical parameters: for example function (1) can be represented with two discrete parameters 
KIFN-γ,{ }=0 and KIFN-γ,{TGF-β}=1.The parameter KIFN-γ,{ }=0 indicate that the inhibitor TGF-β 
of IFN-γ is above its threshold and therefore its influence on the IFN-γ will be to degrade to low 
level (0 level). The K parameters are also called attractors as they attract the expression levels of 
entities to their values. Table 3.9 shows all the equivalent parameters of functions (1-3). 
 
Boolean Functions Logical Parameters 
1 KIFN-γ,{ }=0,   
KIFN-γ,{TGF-β}=1 
2 KIDO,{ }=0,   
KIDO,{IFN-γ}=1,   
KIDO,{TGF-β}=1,   
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Table: 3.9 Logical parameters of IFN-γ, IDO and TGF-β 
 
 
KIDO,{IFN-γ, TGF-β}=1 
3 KTGF-β,{ }=0,   
KTGF-β,{IFN-γ}=1,  
KTGF-β,{IDO}=1,  
KTGF-β,{IFN-γ, IDO}=1 
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RESULTS 
 
4.1 Expression of IDO in H69 cell line 
 
A chronic cholestatic liver disease such PBC has mostly affected women in populations around 
the globe (male to female ratio is approximately 1 to 10). PBC primarily affects middle-aged 
women. The female predominance may hold an important key to PBC etiology (Prince et al., 
2002; Kaplan et al., 2005). PBC is a chronic inflammatory autoimmune disease that mostly 
targets the cholangiocytes of the interlobular bile ducts in the liver. Generally IDO is expressed 
from different lymphocytic and non lymphocytic cell population. In order to investigate the 
effect of various inflammatory stimuli in the induction of immunoregulatory molecule such as 
IDO, TGF-β and sencence marker p21, we used H69 cell line for the current study. An 
immortalized biliary epithelial cell line (iBEC) (H69) was created by Grubman (Grubman et al., 
1994) from human intrahepatic biliary epithelial cells. Brain et al. established an in vitro model 
using H69 cells to investigate the link between senescence and epithelial cell differentiation 
(Brain et al., 2013). H2O2 treatment is not only mimicking the in vivo oxidative stress condition 
but is recently reported to be a model for oxidative stress induced spontaneous differentiation. 
Here we assessed the expression of mRNA encoding IDO-1, IDO-2, TGF-β1, TGF-β2 and p21 
(primers validated data not shown) following stimulation of H69 cells with H2O2, IFN-γ and LPS 
for 6 and 24 hours respectively [Supplementary data (Figure:1, 2, 3)]. RNA was extracted 
[Supplementary data (Figure: 4)] and cDNA was prepared [Supplementary data (Figure: 5)]. 
Figure: 4.1 demonstrates significant increase in the expression of IDO-1 with H2O2, IFN-γ and 
LPS at 6 hours and 24 hours in cells treated with H2O2 and LPS. However the increase at 24 
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hours is reduced compare to the increase at 6 hours. The results shown are normalized against 
the housekeeping gene, GAPDH.  Stimulation of H69 cells with IFN-γ results in a 6644 fold 
increase of IDO expression at 6 hours. However, stimulation with H2O2 or LPS resulted in 51 
and 4 fold increase respectively. The difference between IFN-γ stimulated compared with H2O2 
or LPS stimulated groups was statistically significant (p<0.05).  High level of IDO-1 expression 
was sustained at 24 hours in IFN-γ treated cells; whereas no detectable expression of IDO was 
found in untreated H69 cells (data not shown).  There was no significant upregulation in the 
expression of p21with with H2O2, IFN-γ and LPS.  
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Figure 4.1: Quantification of IDO-1/2, TGF-β1/2 and p21 mRNA in H69 cells. Cells were treated with 
H2O2 [A, B] (200μΜ), IFN- γ [C, D] (20ng/ml) and LPS [E, F] (1μg/ml) for 6 and 24 hours respectively. 
RNA was extracted and cDNA was prepared. mRNA for target genes was normalized to GAPDH using 
real-time PCR. Data are given as the means of the results of three individual experiments. Bars indicate 
standard deviations. Data analysis was performed using REST 2009 software.  
There was no significant upregulation in the expression of TGF-β1 with H2O2, IFN-γ and 
LPS.TGF-β2 was significantly upregulated in cells treated with H2O2 (6 fold), IFN-γ (12 fold) 
and LPS (3fold) at 6hours. The level of expression was reduced at 24 hours. 
 
4.2 Expression of IDO in the H69 cell line in presence of TGF-β pathway 
inhibitor 
 
In order to determine whether the IDO-1 expression is dependent on TGF-β pathway or not in 
our model, cells were incubated with a TGF-β type I receptor serine/threonine kinase (ALK5) 
inhibitor (SB-505124), (Callahan et al., 2002) at an optimal concentration of 1µΜ, for one hour 
before stimulation with IFN-γ, H2O2 or LPS. Here we assessed the expression of mRNA 
encoding IDO-1, IDO-2, TGF-β1, TGF-β2 and p21 following stimulation of H69 cells with 
H2O2, IFN-γ and LPS for 6 and 24 hours respectively. RNA was extracted [Supplementary data 
(Figure: 6)] and cDNA was prepared [Supplementary data (Figure: 7)]. The expression of IDO-1 
was not significantly different between the treated and untreated group except IFN-γ. The results 
shown are normalized against the housekeeping gene, GAPDH.  Stimulation of H69 cells with 
IFN-γ results in a 26987 fold increase of IDO expression at 6 hours. However, stimulation with 
H2O2 or LPS resulted in 1.49 and 4.6 fold increase respectively. The difference between IFN-γ 
stimulated compared with H2O2 or LPS stimulated groups was statistically significant. Even 
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though the expression of IDO-2 was detected in H69 cell but the difference was not significant as 
compared to others. These findings suggest that the IDO-1 expression in H69 cells is inducible 
with dramatic increase following IFN-γ stimulation but independent of TGF-β pathway.  
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Fig: 4.2 Quantification of IDO mRNA pretreated with TGF-β blocker and then H2O2, IFN- γ, LPS 
in H69 cells. Cells were pretreated with 1μM of TGF-β type I receptor (ALK5) inhibitor SB-505124 for 
1hour at 37 C before treating with H2O2 (200μΜ), H2O2 [A, B] (200μΜ), IFN- γ [C, D] (20ng/ml) and 
LPS [E, F] (1μg/ml) for 6 and 24 hours respectively. RNA was extracted and cDNA was prepared. 
mRNA for target genes was normalized to GAPDH using real-time PCR. Data are given as the means of 
the results of three individual experiments. Bars indicate standard deviations. Data analysis was 
performed using REST 2009 software. 
4.3 The expression of IDO in H69 cell line is highly responsive to IFN-γ 
stimulation 
 
We investigated the effect of IFN-γ, H2O2, and LPS at protein level in H69 cells Figure: 4.3. We 
conducted western blot analysis to examine the effects of these stimulants. H69 cells were 
treated with H2O2 (200μΜ), IFN-γ (20ng/ml) and LPS (1μg/ml) for 48 Hours.  
 
 
 
Fig: 4.3 The expression of IDO protein in H69 cells assessed by western blot. H69 cells were treated 
with H2O2 (200μΜ), IFN- γ (20ng/ml) and LPS (1μg/ml) for 48 hours. IFN-γ induced IDO protein 
expression in H69 cells. Cells were recovered and western blotting performed by using anti-IDO 
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antibodies (abcam) to check the expression of IDO. Data are representative of three independent 
experiments. 
 
Protein was quantified by Bradford assay [Supplementary data (Figure: 10)]. The IDO 
expression was noticed within 48 Hours in the presence of IFN-γ. IFN-γ is a known potent IDO 
inducer. These findings propose that IDO expression in H69 cells was an inducible incident that 
was vastly receptive to IFN-γ stimulation.  
 
4.4 Intracellular immunofluorescence analysis of the expression of IDO in H69 
cells  
 
H69 Cells were treated with H2O2 (200μΜ), IFN-γ (20ng/ml) and LPS (1μg/ml) for 0, 48 and 72 
Hours respectively, the significantly high IDO expression was observed as compared to the 
untreated (Figure. 4.4A). These data suggest that H69 cells expressed IDO in the presence of 
H2O2, IFN-γ and LPS. The expression of IDO was higher in the presences of IFN-γ as compare 
to the H2O2 and LPS. In Figure 4.4B H69 cells were pretreated with 1μM of TGF-β type I 
receptor (ALK5) inhibitor SB-505124 for 1hour at 37 C before treating with H2O2 (200μΜ), 
IFN-γ (20ng/ml) and LPS (1μg/ml) for 0, 48 and 72 Hours respectively, there is high IDO 
expression detected after blocking with TGF-β type I receptor (ALK5) inhibitor as compared to 
the untreated. These results are in the favor of the RT-PCR data as shown in Figure 4.2 that IDO 
expression in H69 was independent of TGF-β pathway. 
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Figure 4.4: The expression of IDO protein in H69 cells assessed by Immunofluorescence. H69 Cells 
were treated with H2O2 (200μΜ), IFN-γ (20ng/ml) and LPS (1μg/ml) for 0, 48 and 72 Hours respectively 
(A). H69 Cells were pretreated with 1μM of TGF-β type I receptor (ALK5) inhibitor SB-505124 for 
1hour at 37 C before treating with H2O2 (200μΜ), IFN- γ (20ng/ml) and LPS (1μg/ml) for 0, 48 and 72 
Hours respectively (B). Densitometer analysis performed on each image (C). The nuclear staining is 
shown graphically. Images were captured at x100 magnification. Graph represents the mean pixel 
intensity of IDO antibody staining. 3 technical replicates were performed and the experiment repeated, n 
= 3. An isotype control instead of primary IDO antibody was used to provide a threshold level of 
fluorescence against which the treated cells fluorescent staining was compared. 
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4.5 The enzymatic activity of IDO is up regulated by IFN-γ, H2O2 and LPS 
stimulation in H69 cell line  
 
Some current studies have shown an inconsistency between the expression of IDO and its 
enzymatic activity. Hence we examined the enzymatic activity of IDO in H69 cells. We used 
HPLC to measure the levels of L-tryptophan and its metabolite, L-kynurenine, in the culture 
supernatants (Figure: 4.5A). Standard curve showed in supplementary data (Figure: 11). Cells 
were stimulated with IFN-γ, H2O2 or LPS for up to 120 hours.  The supernatant of unstimulated 
H69 cells showed no L-kynurenine production. In supernatants of H69 cells stimulated by IFN-γ, 
H2O2 or LPS, L-kynurenine was found at 22± µmol/ml, 0.9± and 0.8± µmol/ml, respectively. 
The difference of L-kynurenine levels between the IFN-γ stimulated or H2O2/LPS stimulated 
H69 cells and the unstimulated H69 cells was significant (p<0.05). Highest L-tryptophan levels 
were found in unstimulated H69 cells (50± µmol/ml) while the L-tryptophan concentrations were 
significantly reduced in the supernatants of IFN-γ stimulated H69 cells (0.6±0.04 µmol/ml) and 
in supernatants of H2O2 or LPS stimulated cells at 120 hours (18±0.1 µmol/ml). No statistical 
differences were found between the H2O2 and the LPS stimulated group. 
Additionally, IDO enzymatic activity was also determined by colorimetric assay, results were 
similar to those obtained with HPLC, although less sensitive (Figure 4.5B). Standard curve of 
Kynurenine showed in (supplementary data, Figure 12). 
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Figure: 4.5 Measurement of IDO enzymatic activity in H69 cell supernatants. H69 cells were 
prepared with stimuli consisting of H2O2 (200μΜ), IFN-γ (20ng/ml) and LPS (1μg/ml) at 0 to 120 hours. 
Supernatants were harvested and evaluated for kynurenine production using HPLC (A).  
H69 cells were prepared with stimuli consisting of H2O2 (200μΜ), IFN-γ (20ng/ml) and LPS (1μg/ml) at 
0 to 120 hours.  Enzymatic activity was quantified by the colorimetric assay (B) for kynurenine. 
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4.6 Tryptophan metabolites induce T regulatory cell phenotype from the 
whole human CD4+ T cell population 
 
We examined the effect of the kynurenines on the number of FOXP3 positive cells from the 
whole human CD4+T cell population. CD4+T cells were stimulated with anti-CD3/CD28 beads 
[supplementary data, Figure: 13] in the presence of the kynurenines (L-Kynurenine, 
3Hydroxykynurenine, 3Hydroxyanthralinic acid), 50 μM for 5 days. As shown in Fig.4.6, there 
was no significant difference in the proportion of CD4+ cells expressing FoxP3 in the presence of 
any of the kynurenines as compare to the control after 5 days. However Flow histograms of 3HK 
showed a significant up regulation in the fraction of CD4+ cells expressing FoxP3 in three 
independent experiments.  
 
A 
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Fig: 4.6 FoxP3 expression in Human CD4+ T cells cultured with kynurenines. CD4+ T cells were 
activated with CD3/CD28 beads with or without kynurenines. At 5 days, cells were retrieved and the 
proportion of CD4+ T cells that are FOXP3 positive was determined by intracellular flow cytometry (A, 
B). Results are representative of at least three independent experiments.  
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4.7 IDO activity in PBC patient sera  
 
IDO activity was measured as the ratio of the level of L-Kynurenine and level of L-Tryptophan. 
We found higher IDO activity in sera from PBC patients (n=47) as compared to the healthy 
controls (n=24). We found statistically significant differences in both groups when measured the 
area and height of peaks respectively through HPLC Figure: 4.7. Kynurenine and Tryptophan 
ratio (Area), Kynurenine and Tryptophan ratio (Height) showed in supplementary data Figure: 
14. 
 
 
 
Fig: 4.7 The IDO enzymatic activity in serum samples of healthy and PBC patients through HPLC. 
Kynurenine and Tryptophan concentrations were measured by HPLC in serum samples collected from 24 
healthy donors and from 47 PBC patients. Statistical analyses were used to compare each control group 
vs. patient group.  
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4.8 Expression of IDO in biliary epithelial cell from the Healthy control 
 
To investigate the expression of IDO, immunohistochemistry was performed on normal liver 
tissues. IDO-positive staining was not noticed among the biliary epithelial cells of normal liver 
tissues (A, B, C and D) except minimal expression in hepatocytes (E and F) Figure 4.8. 
 
 
 
A B 
C D 
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Figure: 4.8 Expression of IDO in healthy liver biopsies. The expression of IDO in liver tissues was 
examined in samples from healthy controls (n=5) using anti-IDO antibody, as described in material and 
methods. No expression was observed in cholangiocytes of healthy controls (A, B, C, and D). Minimal 
expression was detected in hepatocytes (E, F).  
4.9 Expression of IDO in biliary epithelial cell from the patients with PBC 
 
To check the IDO expression in PBC patients, the immunohistochemical assay was conduct in 
sections from PBC patients. Some discrete staining is shown in BEC (Panels A and F). IDO 
expression was very high in periportal hepatocytes in conjunction with notable interface hepatitis 
(Figure: 4.9). High expression of IDO observed in the cholangiocytes (A, B, C, D, E and F) of 
PBC patients. The high expression of IDO was noticed in damaged hepatocytes as well (G, H, I 
and J). 
 
E F 
Chapter 4  Results 
80 
 
 
 
 
 
A 
C 
F E 
D 
B 
Chapter 4  Results 
81 
 
 
 
 
 
 
Fig: 4.9 Expression of IDO in PBC liver biopsies. The expression of IDO in liver tissues was examined 
in samples from patients with PBC (n=5) using anti-IDO antibody, as described in material and methods. 
High expression of IDO reveled in the cholangiocytes (A, B, C, D, E and F) of PBC patients. The high 
expression of IDO was noticed in damaged hepatocytes (G, H, I and J). Images were captured at x100 
magnification. 
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4.10 Expression of FoxP3 in biliary epithelial cell from the patients with PBC 
 
In order to attain clinical confirmation of FoxP3 expression in PBC, the immunohistochemistry 
was conducted on PBC specimens (liver tissues). Sections from the same PBC patients stained 
for FoxP3 are shown in panels A – D. Foxp3+ cells were morphologically small lymphocytes. 
There is a clear increase in number with inflammation, particularly with interface hepatitis and 
IDO expression. 
 
 
 
A B 
C D 
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Figure: 4.10 Expression of FoxP3 in PBC liver biopsies. Sections from the same PBC patients stained 
for FoxP3. There is a clear increase in number with inflammation, particularly with interface hepatitis and 
IDO expression. Images were captured at x100 magnification.  
4.11 Expression of IDO in acute rejected transplanted liver section 
 
To accomplish clinical substantiation of IDO expression in transplanted patient, the 
immunohistochemistry was conducted on liver tissues. High IDO-positive staining was noticed 
(A, B) and mild in Panel C-D in hepatocytes (Figure 4.11). 
 
 
 
A B 
C D 
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 Fig: 4.11 Expression of IDO in PBC liver biopsies of acute transplanted rejected patients. The 
expression of IDO in liver tissues was examined in samples from patients with acute transplanted rejected 
patients (n=5) using anti-IDO antibody, as described in material and methods. High expression of IDO 
reveled in the hepatocytes (0–70%) of patients. Images were captured at x100 magnification. 
4.12 Expression of IDO in liver biopsies from the patients with HCV induced 
liver cirrhosis 
 
In order to get clinical validation of IDO expression in HCV patients, the immunohistochemical 
assay was conducted on HCV specimens (liver tissues). Immunohistochemical recognition 
revealed that IDO was overexpressed in 28 of 35 (80%) cirrhotic liver samples, whereas 5 of 35 
(14.2%) cases presented moderate and 2 of 35 (5.7%) cases presented mild expression of IDO. 
Mild expression of IDO revealed in the hepatocytes of HCV patients (A). Moderate expression 
of IDO revealed in the hepatocytes of HCV patients (B). The high expression of IDO was 
noticed in hepatocytes (C). Figure: 4.12.  
 
A 
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Fig: 4.12 Expression of IDO in HCV liver biopsies. The IDO protein expression in liver tissues was 
examined in samples from patients infected with HCV (n=35) using anti-IDO antibody, as described in 
material and methods. Mild (A), Moderate (B) and high expression of IDO was noticed in hepatocytes of 
HCV patients(C). Images were captured at x100 magnification. 
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4.13 IDO activity in HCV patient sera 
It was imperative to check IDO enzymatic activity, because there has been a documented 
incongruity between IDO activity and expression. The functional enzymatic activity of IDO may 
be determined by quantifying kynurenine (the first catabolite in kynurenine pathway) we got 
benefit of (96-well assay) colorimetric assay for determination of kynurenine. To confirm this 
approach, we established a standard curve for quantifying kynurenine. We observed significantly 
high level of kynurenine as compared to the control group.  
 
Fig: 4.13 The IDO enzymatic activity in serum samples through Colorimetric assay. Enzymatic 
activity was measured by the colorimetric assay, as described in the Methods section. Kynurenine levels 
were measured by colorimetric assay in 200 different samples. The graph displays the results.  
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4.14 GenoTech Results 
   
Qualitative model of the IDO related BRN is shown in (Figure 4.15) as a state graph.  Each node 
of the state graph represents the state of the BRN in the form expression levels of the entities in 
the order of IFN-γ, IDO and TGF-β. The edges show the evolution (transition) of the network 
from one state to another state.  The evolution can be further seen as paths (alternating sequence 
of states and transitions).  A closed path starts and ends with the same state.  A stable state in 
state graph is the one which does not evolve to other state.  Cycles and stable states represent 
important observation of the BRN. 
We observe two types of steady states behaviors in the state graph. The cycle (0,0,0) (0,1,0) 
(0,1,1) (0,0,1) (0,0,0)  and the stable state (1,1,0). The cycle shows the homeostasis of IDO and 
TGF-β while IFN-γ is inactive (silent). The stable state shows the high expression levels of IFN-
γ and IDO while TGF-β is silent.  There is a divergence from the cycle towards the stable states 
and it is observed that this divergence occurs when IFN-γ has expression levels. The snapshots of 
the BRN modeling in GenoTech tool are shown in Figures 4.16 and 4.17. 
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Fig: 4.14 Boolean model of IDO-related BRN: The entities in oval represent proteins (IFN-γ, IDO, 
TGF-), which are connected by two types of interactions i.e. activation (blue) e.g. IFN-γ activates IDO 
at expression level 1 and inhibition (red) IFN-γ inhibits TGF- at expression level 1,  with associated 
threshold. 
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Fig: 4.15 The state graph of the IDO BRN shows the steady states, (order of protein in steady state is: 
IFN-γ, IDO and TGF-) which lead to cycle, in green, depicting homeostasis and a stable steady state 
(110), red, in which IFN and IDO are overexpressed while TGF- is inactive. The deviation towards 
stable state is represented by dotted line. 
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Fig: 4.16 Snapshot of Genotech modeling of IDO-BRN: The windows show the K-parameters of IFNG 
(IFN-γ). 
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Fig 4.17 Discrete model in GenoTech. The red state shows the stable state of the BRN (pathological 
state). The closed path represents the homeostasis IDO and other entities. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Chapter 4  Results 
92 
 
4.18 Supplementary Data 
 
H69-cells treated with H2O2 
 
We investigated the effect of H2O2, on the expression of IDO in the H69 cell line. We treated the 
H69 cells with 200μM H2O2 for (0, 6, 24 Hours). 
 
 
Figure:1 H69 cells treated with 200μM H2O2 for (0, 6, 24 Hours). 
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H69-cells treated with IFN-γ 
 
We inspected the effect of IFN-γ, on the expression of IDO in the H69 cell line. We treated the 
H69 cells with 40ng/ml IFN- γ for (0, 6, 24 Hours). 
 
 
Figure: 2 H69 cells treated with 40ng/ml IFN- γ for (0, 6, 24 Hours). 
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H69-cells treated with LPS 
 
We checked the effect of LPS, on the expression of IDO in the H69 cell line. We treated the H69 
cells with 1μg/ml LPS for (0, 6, 24 Hours). 
 
 
 
Figure: 3 H69 cells treated with 1μg/ml LPS for (0, 6, 24 Hours). 
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RNA extraction from H69 cells treated with H2O2, IFN-γ and LPS 
 
H69 cells are treated with H2O2 , IFN-γ and LPS. RNA extracted from H69 cells. 
 
2000
1000
1 2 3 4 5 6 7 8
 
Figure: 4 RNA extraction from H69 cells treated with H2O2, IFN-γ, and LPS. 1% agarose gel 
showing 1kb Ladder, H2O2 6 hr, H2O2 24 hr, IFN- γ 6hr, IFN- γ 24hr, LPS 6hr, LPS 24hr, and untreated in 
lane 1,2,3,4,5,6,7,8 respectively.  
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cDNA generation from H69 cells treated with H2O2, IFN-γ and LPS. 
 
cDNA generated from H69 cells after extraction of RNA.  
 
500
1 2 3 4 5 6 7 8
 
Figure: 5 cDNA generation from H69 cells treated with H2O2, IFN-γ and LPS.1% agarose gel 
showing 100bp Ladder, H2O2 6 hr, H2O2 24 hr, IFN- γ 6hr, IFN- γ 24hr, LPS 6hr, LPS 24hr, and untreated 
in lane 1,2,3,4,5,6,7,8 respectively.  
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RNA extraction from H69 cells blocking with TGF-β, treated with H2O2, IFN-
γ, and LPS. 
 
H69 cells blocked with TGF-β as describe in material and methods and treated with H2O2, IFN-γ 
and LPS then RNA extracted from H69 cells. 
 
2000
1000
1 2 3 4 5 6 7 8
 
Figure: 6 RNA extraction from H69 cells blocking with TGF-β, treated with H2O2, IFN-γ, and 
LPS. 1% agarose gel showing 1kb Ladder, H2O2 6 hr, H2O2 24 hr, IFN- γ 6hr, IFN- γ 24hr, LPS 6hr, LPS 
24hr, and untreated in lane 1,2,3,4,5,6,7,8 respectively.  
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cDNA generation from H69 cells blocking with TGF-β, treated with H2O2, 
IFN-γ, and LPS. 
 
cDNA generated from H69 cells blocking with TGF-β after extraction of RNA.  
 
500
1 2 3 4 5 6 7 8
 
Figure: 7 cDNA generation from H69 cells blocking with TGF-β, treated with H2O2, IFN-γ, and 
LPS. 1% agarose gel showing 100bp Ladder, H2O2 6 hr, H2O2 24 hr, IFN- γ 6hr, IFN- γ 24hr, LPS 6hr, 
LPS 24hr, and untreated in lane 1,2,3,4,5,6,7,8 respectively.  
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Amplification Plot of real-time PCR  
 
The amplification plot obtained from the real time PCR when the experiment was performed to 
check the expression of IDO without blocking with TGF-β. 
 
 
 
Figure: 8 Amplification Plot (1) of real-time PCR. qPCR amplification plot depicting GOI 
amplification curves plotted against cycle number. The Ct value is used to calculate relative gene 
expression against an untreated sample and a housekeeping gene as described above. 
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Amplification Plot of real-time PCR 
 
The amplification plot obtained from the real time PCR when the experiment was performed to 
check the expression of IDO blocking with TGF-β. 
 
 
 
Figure: 9 Amplification Plot (2) of real-time PCR qPCR amplification plot depicting GOI 
amplification curves plotted against cycle number. The Ct value is used to calculate relative gene 
expression against an untreated sample and a housekeeping gene as described above. 
 
 
Chapter 4  Results 
103 
 
Protein determination 
Standard curve for Protein
2000 1000 500 250 125
 
Standard curve for protein
 
Figure: 10 The concentration of protein was determined through Bradford assay: standard curve. 
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Standard curve of Kynurenine and Tryptophan
 
Figure: 11 Standard curve of Kynurenine and Tryptophan: The Kynurenine (Area and Height), 
Tryptophan (Area and Height) standard curve. Standard curve drawn before conducting the HPLC. 
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IFN-γ
H2O2
LPS
100μM 50μM 25μM 12.5μM 6.25μM
-ve control
120 6 24 9648 72 120 0 6 12 24
2448 4872 7296 96120 1201260
Standard curve for Kynurenine
H-69 cell treated with IFN-γ,LPS, H2O2 at  0hr,6hr,12hr,24hr,48hr,72hr,96hr,120hr  
Standard curve of Kynurenine
 
Figure: 12 Standard curve of Kynurenine: The assay was performed in the 96 well plate. Standard 
curve draw before conducting the colorimetric assay. 
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HumanCD4+ T cell treated with Tryptophan 
metabolites
Control L-Kyn 3HK 3OHAA
TGF-β
 
 
 
Figure: 13 CD4+ T cells were stimulated with anti-CD3/CD28 beads in the presence of the 
kynurenines. CD4+ T cells were activated with CD3/CD28 beads with or without kynurenines. L-
Kynurenine (L-Kyn), 3Hydroxykynurenine (3HK), 3Hydroxyanthralinic acid (3OHAA), 50 μM for 5 
days. TGF-β taken as positive control. 
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Kynurenine (Area) Control vs. PBC
Kynurenine (Height) Control vs. PBC
 
Figure: 14 The IDO enzymatic activity in serum samples through HPLC. Kynurenine and 
Tryptophan concentrations were measured by HPLC in serum samples collected from 24 healthy donors 
and from 47 PBC patients. Statistical analyses were used to compare each control group vs. patient group. 
Kynurenine and Tryptophan ratio (Area), Kynurenine and Tryptophan ratio (Height). 
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DISCUSSION 
 
The first and rate-limiting step of tryptophan catabolism through kynurenine pathway is initiated 
by an intra-cellular enzyme IDO. IDO is a single chain, heme containing oxidoreductase that 
catalyzes the oxidative cleavage of 2,3 double bond of indole ring (Grohmann et al., 2003). This 
enzyme plays a crucial role in conditions like autoimmunity, infections and malignancies (Munn 
et al., 1998; Oyama et al., 1998; Mellor et al., 2004; Munn et al., 2004a). The evidence in this 
study suggests a key role of IDO in Primary biliary cirrhosis. The current study establishes, for 
the first time, the expression of IDO in the H69 cell line and increase rate of conversion of 
tryptophan to kynurenine in patients with PBC. Furthermore, clinical biopsies from PBC patients 
demonstrated that the expression of IDO was observed not only in cholangiocytes as described 
earlier (Oertelt-Prigione et al., 2008) but also in hepatocytes. There are a limited number of 
reports of human biliary cell lines that have been isolated from the gallbladder, common bile 
duct, and primary tumors of the liver (Knuth et al., 1985; Yamaguchi et al., 1985; Miyagiwa et 
al., 1989; Sirisinha et al., 1991; Iemura et al., 1992; Yano et al., 1992). The H69 cell line was 
created by Grubman (Grubman et al., 1994) from human intrahepatic biliary epithelial cells.   
 
Cholestatic liver diseases such as PBC, characterized by injury to small and medium bile ducts, 
progressive inflammation, portal fibrosis, cholestasis and cirrhosis (Rygiel et al., 2008). Oertelt-
Prigione et al. 2008 described that abnormalities in the IDO pathway, might play a role in the 
pathogenesis of PBC. They demonstrated for the first time that IDO is expressed at the luminal 
surface of cholangiocytes, as described in other epithelia (Shirey et al., 2006; Zegarra-MoranO et 
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al., 2004). Interestingly, the expression of IDO was identified within few damaged cholangiocyte 
aggregates, thus implying a potential role in immunogenicity (Oertelt-Prigione et al., 2008). 
 
Indo gene encodes the IDO protein which is an apo-enzyme in nature. This is a 15 kb, conserved 
gene and is present on human chromosome 8 (Suzuki et al., 2003). The transcription of this gene 
is strictly regulated by a limited number of inflammatory mediators. Multiple sequence elements 
are located in the promoter of Indo gene that respond differently to different types of interferon 
especially interferon gamma (Suzuki et al., 2003). IFN-regulatory factor 1 (IRF1) and Signal 
transducer and activator of transcription 1 (STAT1) acts synergistically to induce the interferon-
gamma mediated expression of IDO (Chon et al., 1996). IDO expression that is induced by IFN-
γ has been reported up to 100 times more persuasive than IFN-α or IFN-β (Taylor et al., 1991). 
Although interferon gamma is the key inducer of IDO expression, yet it is not essential to induce 
the expression of this enzyme. The IDO oxidation (Taylor et al., 1991) is sensitive even at low 
micromolar concentrations of H2O2 (Mellor et al., 1999).  Lipopolysaccharides (LPS) act along 
with Tumor Necrosis Factor (TNF) to induce the in-vivo expression of IDO via an interferon 
gamma independent pathway (Fujigaki et al., 2001). Prior studies proposed that, under certain 
condition IDO can be induced through IFN-γ dependent or independent pathways (Saito et al., 
1993; Saito et al., 1996). IDO is up-regulated by IFN-γ and down-regulated by IL-4 and TGF-β 
(Musso et al., 1994; Yuan et al., 1998).  
 
We initially evaluated the transcriptional profile of IDO in H69 cells after direct stimulation with 
IFN-γ, H2O2 and LPS and observed significantly increased expression at transcription level.  
Additionally, we found that IFN-γ induced IDO expression in H69 cells at concentration as low 
as 20ng/ml.  This would suggest that the expression of IDO in H69 cells is highly responsive to 
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IFN-γ stimulation. However, expression of protein as detected by western blot was only seen 
following stimulation with IFN-γ. Our data is in agreement with earlier studies which show that 
IFN-γ can induce IDO expression in several cell types and is produced by inflammatory cells in 
response to immune activation (Billiau et al., 2009). IFN-γ may have immunopathogenic 
importance in primary biliary cirrhosis (Fracchia et al., 2000). 
 
TGF-β is a member of a cytokine superfamily consisting of 42 members with six subgroups: 
TGF-β, Bone morphogenetic proteins (BMPs), growth and differentiation factors, inhibins and 
activins. All the members of this family share a similar structure and are secreted as 
homodimeric pro-proteins (Massague et al., 1990). There are three human TGF-β isoforms: 
TGFβ-1, TGFβ-2 and TGFβ-3 and are potent pro-fibrogenic cytokines (Lawrence et al., 1996). 
The TGFβ-1 isoform is known to regulate the differentiation and proliferation of many cell types 
within the body and it has a role in immunomodulation when produced by regulatory T cells. 
Less is known about TGFβ-2 and TGFβ-3, although they have been described as having role in 
embryogenesis and wound healing (Flanders et al., 2004). The role of TGF-β in senescence was 
first shown by Tremain in murine keratinocytes (Tremain et al., 2000). TGF-β signaling has also 
been shown to induce pro-EMT transcription factor SNAIL through SMAD activation (Kaimori 
et al., 2007). In cancer patients suffering from immunosupression, TGF-β and IDO play crucial 
role in this scenario. Inhibition of TGF- β signaling and the blockade of IDO activity may be 
important pathway in that course (Massague, 2008; Popov et al., 2008). In this framework, IDO 
is a pivotal intermediate that associates TGF-β generation by DCs with T-reg differentiation and 
induction of tolerance (Belladonna et al., 2008). Kirby, et al. shown that injured biliary epithelial 
cell becomes inflamed and activates large quantities of TGF-β (Kirby, et al., 2008). We 
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examined the expression of TGF-β I & II in our model. Our data demonstrated that TGF-β I 
levels were not significantly modulated, whereas TGF-β II levels were significantly increased in 
response to IFN-γ, H2O2 and LPS respectively. There was no significant expression of p21 in any 
condition. Furthermore, incubation of cells with a nontoxic pharmacological TGF-β type1 
receptor (ALK5) (SB-505124) (Callahan et al., 2002), followed by stimulation with IFN-γ did 
not have any effect on IDO-1 expression. This suggests that the induction of IDO is IFN-γ 
dependent but independent of the TGF-β pathway in our model.    
 
IDO-2 enzyme was discovered recently, the biological role of IDO-2 in not defined yet. It is 
expressed in the dendritic cell line in the kidney and reproductive system advocating its 
participation in immunomodulation, kidney function and fertility (Baban et al., 2004). 1-methyl 
D-tryptophan is the pharmacological inhibitor of IDO-2, whilst its stereoisomer 1-methyl-L-
tryptophan was more particular for IDO-1 (Metz et al., 2007). IDO-2 provides new insights that 
the kynurenine pathway is involved in different biological processes than previously considered. 
IDO-2 the isoform is expressed in H69 cells but the expression was not significant as compared 
to IDO-1.  
 
IDO catalyzes the initial step of tryptophan catabolism within the biosynthetic pathway of 
nicotinamide dinucleotides, and N-formyl-kynurenine is formed as a first intermediate. The 
kynurenine-to-tryptophan ratio has been a sensitive estimate to monitor the activation status of 
IDO and of cellular immunity both in vivo and in vitro (Werner-Felmayer et al., 1989; Fuchs et 
al., 1990). In patients, an increased level of kynurenine and decrease in serum tryptophan 
indicated the enzymatic activity of IDO, such as autoimmune disorders and malignant diseases 
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(Werner-Felmayer et al., 1989; Giusti et al., 1996; Huengsberg et al., 1998; Fuchs et al., 1990; 
Widner et al., 2000).  
 
Oertelt-Prigione et al. investigated the transcriptional profile of IDO in peripheral blood 
monocytes from PBC patients following with IFN-γ stimulation directly (Oertelt-Prigione et al., 
2008). Several studies highlighted an inconsistency between the expression of IDO and its 
enzymatic activity (Laich et al., 2002; Hwu et al., 2000). To define the functional relevance we 
examined the enzymatic activity of IDO in H69 cells. Increased kynurenine production and 
reduced substrate tryptophan demonstrated the functional enzymatic activity of IDO in H69 
cells. Additionally, we also observed significantly high IDO activity in sera derived from PBC 
patients compared to the healthy controls. However, the limitation is that this pathway is very 
responsive to nonspecific inflammation and is induced in all states of chronic inflammation as 
IDO is a very sensitive IFN-γ responsive gene.  
 
IDO is involved in the fibrotic progression of the liver (Gressner et al., 2002). We examined 
liver sections from PBC patients and confirmed that IDO is expressed in cholangiocytes as 
described in other epithelial cells (Shirey et al., 2006; Zegarra-MoranO et al., 2004). The 
expression of IDO was identified within the cholangiocytes and predominantly in the 
hepatocytes, which indicates its potential role in the immunogenicity.  
 
We have previously shown that mature dendritic cell expand CD4+CD25high regulatory T cells 
in an IDO-dependent manner (Hill et al., 2007). Findings by Fallarino, demonstrated that 
expression of IDO may influence T-regulatory cells (Fallarino et al., 2006 a, b). They established 
that the combined effect of tryptophan depletion and surplus kynurenine involved in the 
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development of FOXP3-expressing CD4+ T-regulatory cell type from naïve CD25– T cells. 
FOXP3 expression was observed in the biopsies from same PBC patients who were exhibiting 
high IDO expression. There is a clear increase in number of FOXP3 cells (Figure: 4.10).  
 
The role of IDO in transplantation was kick-started by decisive data provided by Mellor and 
Munn in pregnancy (Munn et al., 1998). It has also been discovered that upregulation of IDO in 
rejecting grafts is most probably induced by IFN-γ.  In different studies, high IDO activity was 
detected in corneal and cardiac transplant rejection (Beutelspacher et al., 2006; Guillonneau et 
al., 2007). The levels of IDO are up regulated during rejection, they are not adequate to avert or 
considerably delay this process. It is not clear if the rejection process is too strong to be 
overcome by IDO or if inadequate IDO activity is induced in these models. IDO expression was 
detected in hepatocytes from acute rejected transplanted PBC patient’s biopsies.  
 
A recently recognized model demonstrate a vital input to defensive tolerance by the collective 
effects of tryptophan starvation and the generation of tryptophan downstream metabolites 
(communally called ‘kynurenines’), both substantial from IDO activity (Puccetti et al., 2008). 
Zaher et al., 2011 indicated that there were no toxic effects kynurenines or IDO on corneal 
endothelial cells, these results indicating IDO to be part of the ocular immune privilege 
(Beutelspacher et al., 2006; Chen et al., 2006). They observed the effect of topical administration 
of 3HK, these finding suggest that the regulatory pathways may possibly involved (Terness et 
al., 2002).In the present study we have observed whether the tryptophan metabolites can 
modulate Human CD4+ T cells to induce polarization toward T-reg phenotype. Previously, 
Fallarino elucidated an enormous increase in the percentage of naïve FoxP3 expressing cells in 
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the presence of the kynurenines (Fallarino et al., 2006 a, b). We showed an increase in the trend 
of FOXP3 expression in the whole Human CD4+ T cell population in the presence of 3HK 
(Figure: 4.6). 
 
The mechanism of IDO induction during HCV infection is unknown; upregulation of IDO 
expression in the liver has been described in humans with chronic infection and HCV clearance 
was associated with the normalization of IDO level (Larrea et al., 2007). Induction of IDO may 
suppress T-cell reactivity to viral antigen in chronic HCV infection. The high expression of IDO 
contributes to the poor outcome of patients with higher inflammation and liver fibrosis (Larrea et 
al., 2007). Persistently, Ino et al. and Brandacher et al. have shown that increase in the IDO 
expression was interconnected with metastasis in colorectal cancer and endometrial cancer (Ino 
et al., 2006; Brandacher et al., 2006). In this study the IDO expression was investigated in HCV 
infected liver biopsies by immunohistochemistry. The expression of IDO was identified 
predominantly in the cirrhotic hepatocytes. The functional enzymatic activity of IDO was 
determined through colorimetric assay. We observed significantly high level of kynurenine as 
compared to the control group. This also suggests one possible mechanism of IDO mediated 
immune escape employed by HCV in chronic patients. This may also be one of the underlying 
factors for chronic HCV patients to progress to cirrhosis and then gradually to hepatocellular 
carcinoma in an immunosuppressive environment created by IDO.  
 
The biological regulatory network (BRN) links multiple interactions within a cell and allows a 
global perspective of cell working. It assists in understanding the association between molecules 
dictating cellular behaviors (B H Junker ans F Schreiber, 2009). In this study we have modeled 
IDO-associated biological regulatory network (BRN) using the well-known formalism 
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of Rene Thomas. The model showed two types of behaviors, cycles and stable state. Fluctuation 
in the expression level of IDO has been noted in the cycles  
 
The IDO regulates immune responses through inhibiting effector T-cell function (Mellor et al., 
2004). Augmented tryptophan catabolism has been connected with different malignancies and 
autoimmune disorders. The tumors that adapt to the selective pressure of growing in a low-
tryptophan environment might benefit from the toleragenic consequences of local tryptophan 
catabolism. This would be similar to the adaptive exploitation by tumors of other 
immunosuppressive factors that might, at least initially, be deleterious to tumor-cell growth, such 
as TGF-β. TGF-β has also been stated to antagonize IFN-γ-mediated induction of IDO 
expression in human fibroblasts. This seems to run counter to the immunosuppressive activity 
that is ascribed to TGF-β, but it is consistent with the ability of TGF-β to antagonize positively 
regulated targets of IFN-γ (Taylor et al., 1991).IDO is expressed in the tumor cells and adjacent 
stromal cells, and created immunosupression but the mechanism of tumor immune escape in 
different malignancies is not fully understood. IDO is over expressed by different tumor-cell 
types (Uyttenhove et al., 2003). 
 
TGF-β is expressed by most malignant tumors and possibly functions as a tumor suppressor 
early in tumor progression by directly suppressing the propagation of cancer cells (Dumont et al., 
2003; Yingling et al., 2004). As cancer cells progress, they repeatedly become refractory to 
TGF-β-mediated growth inhibition through mutations in the TGF-β receptor (TGF-βR) and/or 
downstream signalling proteins such as Smad proteins, and this can promote epithelial-
mesenchymal transition (EMT) and a metastatic phenotype. Although these cancer cells are no 
Chapter 5  Discussion 
116 
 
longer responsive to TGF-β they continue to overexpress it, and this characteristic is thought to 
contribute to the profound immunosuppression that is observed in patients with advanced or 
metastatic tumors (Dumont et al., 2003; Yingling et al., 2004).Based on the direct effects of 
TGF-β on tumor growth, as well as its effects on the immune system, several approaches to 
develop inhibitors of the TGF-β pathway have been investigated. We observe two types of 
steady states behaviors in the state graph. The cycle (0,0,0) (0,1,0) (0,1,1) (0,0,1) (0,0,0)  and the 
stable state (1,1,0). The cycle shows the homeostasis of IDO and TGF-β while IFN-γ is inactive 
(silent). The stable state shows the high expression levels of IFN-γ and IDO while TGF-β is 
silent.  There is a divergence from the cycle towards the stable states and it is observed that this 
divergence occurs when IFN-γ has expression levels.  
 
The role of IDO in inflammatory condition, cancer and autoimmune diseases is vital. In our 
model we observed the critical role of TGF-β and IFN-γ in the suppression and induction of 
IDO. In cancers condition if we induce TGF-β which is negative regulator of IDO can create the 
homeostasis. Otherwise the expression of IDO can be inhibited by 1-MT. In case of Autoimmune 
diseases perhaps if we inhibit the TGF-β the induction of IDO may produce homeostasis. 
Tryptophan downstream metabolites can also beneficial in this regard. 
 
In conclusion, we demonstrated the expression of IDO in H69 cells was stimulated by IFN-γ, 
H2O2 and LPS respectively. The induction of IDO at tissue level may play a potential role in the 
pathogenesis of diseases. IDO activity is raised in autoimmune disorders and inflammation 
(Schröcksnadel et al., 2006). Interestingly, tryptophan metabolite is able to reverse paralysis in 
mice with experimental autoimmune encephalomyelitis (Platten et al., 2005). IDO 
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immunosuppressive action serves as a negative feedback effect induced by hyperactivation of T-
cell immunity. Although there is increase in Kyn/Trp ratio in PBC patients, there is a possibility 
that current IDO expression is not sufficient to produce the immunosupression. This raises the 
opportunity that the kynurenine metabolites play a pivotal role in disease resolution. The positive 
effect of tryptophan metabolites on Human CD4+ T cells to induce polarization toward T-reg 
phenotype may render a prospective means to ameliorate the consequence of immunotherapy for 
the management of PBC. Furthermore, tryptophan catabolism may offer a potential as a 
biomarker to monitor disease activity in PBC. The enzymatic activity IDO was significantly 
higher in the serum samples of HCV infected patients as compare to the control. We suggest that 
high expression of IDO in progressively cirrhotic livers of HCV Patients might contribute in the 
development of HCC. IDO may characterize novel therapeutic target against HCV.  The 
modeling of the biological regulatory networks (BRNs) using of Rene Thomas Formalism, we 
observe two types of steady states behaviors in this study. These findings recognize prospective 
novel targets for therapy in a range of clinical settings, including, inflammation, tumor resistance 
and autoimmunity. 
Future Prospects 
 
Patients with PBC showed increase rate of tryptophan to kynurenine transformation. We suggest 
that immunoregulatory activity of IDO in PBC might contribute in the progression of disease. 
IDO may represent new therapeutic target against PBC. Tryptophan metabolites may play crucial 
role in this regard. An enzyme with the same biochemical activity to IDO is tryptophan-2,3-
dioxygenase (TDO). This enzyme was originally identified in the liver (Knox et al,. 1950). 
However, as not much is known about the role of TDO in tumorigenesis and its association with 
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IDO. The role of TDO may be investigated in vivo and in vitro models of PBC. From 
transplantation point of view the role of IDO should be investigate as well. It has been shown 
that T-regs maintained in the chronic HCV infection and lead the patients toward cirrhosis. 
Dendritic cells which express IDO enhance the function of T-regs. Therefore this evidence 
proposes a significant role of IDO in HCV infection. We hypothesized that if we inhibit IDO 
activity through 1-MT, it may improve the cellular immune responses in the liver. Thus 
activation of immune system through this mechanism will not only help in clearance of virus but 
it would also increase the survival rate of HCC patients. 
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